

Trying 3106016892...Open

9/124280

Welcome to STN International! Enter x:x  
LOGINID:ssspta1813nxx  
PASSWORD:  
TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Aug 21 CAS patent coverage expanded  
NEWS 3 Aug 24 TABULATE Now Available in More STN Databases  
NEWS 4 Aug 28 MEDLINE from 1958 to Date - Only on STN  
NEWS 5 Sep 7 DGENE GETSIM ALERT: Similarity Current-Awareness  
Searching of Biosequences  
NEWS 6 Sep 11 Textile Technology Digest (TEXTILETECH) now available  
on STN  
NEWS 7 Sep 21 KKF renamed DKILIT  
NEWS 8 Sep 29 The Philippines Inventory of Chemicals and Chemical  
Substances (PICCS) has been added to CHEMLIST  
NEWS 9 Oct 27 New Extraction Code PAX now available in Derwent  
Files  
NEWS 10 Oct 27 SET ABBREVIATIONS and SET PLURALS extended in  
Derwent World Patents Index files  
NEWS 11 Oct 27 Patent Assignee Code Dictionary now available  
in Derwent Patent Files  
NEWS 12 Oct 27 Plasdoc Key Serials Dictionary and Echoing added to  
Derwent Subscriber Files WPIDS and WPIX  
  
NEWS EXPRESS FREE UPGRADE 5.0D FOR STN EXPRESS 5.0 WITH DISCOVER!  
(WINDOWS) NOW AVAILABLE  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:34:20 ON 30 OCT 2000

=> file embase medline biosis uspatfull japio wpids caplus biotechds agricola

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.30	0.30

FILE 'EMBASE' ENTERED AT 11:35:33 ON 30 OCT 2000

COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 11:35:33 ON 30 OCT 2000

FILE 'BIOSIS' ENTERED AT 11:35:33 ON 30 OCT 2000

COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'USPATFULL' ENTERED AT 11:35:33 ON 30 OCT 2000

CA INDEXING COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 11:35:33 ON 30 OCT 2000

COPYRIGHT (C) 2000 Japanese Patent Office (JPO)

FILE 'WPIDS' ENTERED AT 11:35:33 ON 30 OCT 2000

COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE 'CAPLUS' ENTERED AT 11:35:33 ON 30 OCT 2000

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHDS' ENTERED AT 11:35:33 ON 30 OCT 2000

COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE 'AGRICOLA' ENTERED AT 11:35:33 ON 30 OCT 2000

=> e porro massimo/au

E1	1	PORRO MARCELLO A/AU
E2	5	PORRO MARIA GRAZIA/AU
E3	39 -->	PORRO MASSIMO/AU
E4	2	PORRO MIGUEL E/AU
E5	9	PORRO MONICA/AU
E6	1	PORRO N/AU
E7	1	PORRO NICHOLAS D/AU
E8	1	PORRO NOEL M/AU
E9	7	PORRO NOVO N/AU
E10	7	PORRO P/AU
E11	1	PORRO PAOLO/AU
E12	11	PORRO R/AU

=> s e3

L1 39 "PORRO MASSIMO"/AU

=> s l1 and sepsis

L2 8 L1 AND SEPSIS

=> dup rem l8

L8 IS NOT VALID HERE

The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> dup rem l2

PROCESSING COMPLETED FOR L2

L3 7 DUP REM L2 (1 DUPLICATE REMOVED)

=> d bib ab 1-7

L3 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2000 ACS

Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer  
with  
a minimum value of 2. The compositions of the invention bind Lipid-A of  
endotoxins.

L3 ANSWER 4 OF 7 USPATFULL  
AN 94:35369 USPATFULL  
TI Oligosaccharide conjugate vaccines  
IN Porro, Massimo, Siena, Italy  
PA American Cyanamid Company, Wayne, NJ, United States (U.S. corporation)  
PI US 5306492 19940426  
AI US 1992-921678 19920730 (7)  
RLI Division of Ser. No. US 1990-590649, filed on 28 Sep 1990, now  
patented,  
Pat. No. US 5153312  
DT Utility  
EXNAM Primary Examiner: Kim, Kay K.  
LREP Dow, Kenneth J.  
CLMN Number of Claims: 2  
ECL Exemplary Claim: 1  
DRWN 6 Drawing Figure(s); 4 Drawing Page(s)  
LN.CNT 1422

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to an improved method for producing  
oligosaccharide conjugate vaccines. In an additional aspect of the  
invention, oligosaccharide vaccines are produced which elicit a  
monospecific and homogeneous immune response to capsular  
polysaccharide.

A specific embodiment of the invention provides for vaccines which  
induce immunity to prevalent serotypes of Streptococcus pneumoniae.

L3 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2000 ACS  
AN 1993:574225 CAPLUS  
DN 119:174225  
TI Synthetic peptides for detoxification of bacterial endotoxins and  
treatment of septic shock  
IN Porro, Massimo  
PA Italy  
SO PCT Int. Appl., 44 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9314115	A1	19930722	WO 1992-EP1060	19920514
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP,				
	KR, LK, LU, MG, MW, NL, NO, RO, RU, SD, SE, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE, BF, BJ,				
	CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	US 5371186	A	19941206	US 1992-819893	19920116
	AU 9216914	A1	19930803	AU 1992-16914	19920514
	AU 665945	B2	19960125		
	EP 623144	A1	19941109	EP 1992-910229	19920514
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
	FI 9403396	A	19940715	FI 1994-3396	19940715
PRAI	US 1992-819893		19920116		
	US 1991-658744		19910211		
	WO 1992-EP1060		19920514		

AB The novel peptides are R1-(A-B-C)n-R, wherein R1 and R are independently  
H  
or an amino acid residue or a fatty acid residue; A = Lys, Arg, or His; B  
= Phe, Tyr, or Trp; C = Leu, Ile, or Val; and n = 1-100. The peptides  
are  
used for prevention or treatment of septic shock, for the detection of

endotoxin, and for prepn. of a safe antigenic complex of lipid A for producing anti-lipid A antibody.

L3 ANSWER 6 OF 7 USPATFULL  
AN 92:82892 USPATFULL  
TI Oligosaccharide conjugate vaccines  
IN Porro, Massimo, Siena, Italy  
PA American Cyanamid Company, Wayne, NJ, United States (U.S. corporation)  
PI US 5153312 19921006  
AI US 1990-590649 19900928 (7)  
DT Utility  
EXNAM Primary Examiner: Nucker, Christine M.; Assistant Examiner: Kim, Kay  
LREP Dow, Kenneth J.  
CLMN Number of Claims: 27  
ECL Exemplary Claim: 1  
DRWN 6 Drawing Figure(s); 4 Drawing Page(s)  
LN.CNT 1491

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to an improved method for producing oligosaccharide conjugate vaccines. In an additional aspect of the invention, oligosaccharide vaccines are produced which elicit a monospecific and homogeneous immune response to capsular polysaccharide.

A specific embodiment of the invention provides for vaccines which induce immunity to prevalent serotypes of Streptococcus pneumoniae.

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2000 ACS  
AN 1993:463064 CAPLUS  
DN 119:63064  
TI Synthetic peptides for detoxification of bacterial endotoxins and for prevention and treatment of septic shock  
IN Porro, Massimo  
PA Italy  
SO S. African, 40 pp.  
CODEN: SFXAB  
DT Patent  
LA English  
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ZA 9200943	A	19921125	ZA 1992-943	19920210
PRAI	US 1991-658744		19910211		

AB The title peptides, e.g. Lys-Phe-Leu-contg. peptides (I), are effective in the treatment of septic shock by binding with the lipid A moiety of endotoxins. The peptides are also useful as a diagnostic probe for detection and quantitation of endotoxin in blood. The activity of the peptides were confirmed by the direct microprecipitin assay with Bacillus pertussis lipid A and lipopolysaccharide. Actinomycin D-sensitized mice were i.v. treated with I and challenged by i.p. injection of Escherichia coli endotoxin; a survival rate after 7 days was 40%, compared to 30% and 5% for polymixin B-treated control group and saline-treated control group, resp.

=> d his

(FILE 'HOME' ENTERED AT 11:34:20 ON 30 OCT 2000)

FILE 'EMBASE, MEDLINE, BIOSIS, USPATFULL, JAPIO, WPIDS, CAPLUS, BIOTECHDS, AGRICOLA' ENTERED AT 11:35:33 ON 30 OCT 2000  
E PORRO MASSIMO/AU

L1 39 S E3

AN 2000:84285 CAPLUS  
 DN 132:136410  
 TI Vaccines for prevention of gram-negative bacterial infections and endotoxin-related diseases  
 IN Porro, Massimo  
 PA Biosynth S.R.L., Italy  
 SO Eur. Pat. Appl., 40 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 976402	A2	20000202	EP 1999-202476	19990727
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRAI US 1998-124280 19980729

AB A vaccine is disclosed which is useful for protecting a host from Gram neg. infections and the effects of endotoxin, therefore preventing sepsis and septic shock. The vaccine is prepd. by combining LPS free or in conjugate form with a stoichiometric excess of a peptide of the formula: (a) (A)<sub>n</sub> wherein A is Lysine or Arginine and n is an integer with a min. value of 7; (b) (AB)<sub>m</sub> wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a min. value of 3; and (c) (ABC)<sub>p</sub> wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a min. value of 2.

L3 ANSWER 2 OF 7 BIOSIS COPYRIGHT 2000 BIOSIS DUPLICATE 1

AN 2000:173998 BIOSIS

DN PREV200000173998

TI Influence of synthetic antiendotoxin peptides on Lipopolysaccharide (LPS) recognition and LPS-induced proinflammatory cytokine responses by cells expressing membrane-bound CD14.

AU Iwagaki, Akitaka; Porro, Massimo; Pollack, Matthew (1)

CS (1) Department of Medicine, F. Edward Hebert School of Medicine, Uniformed

Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD, 20814 USA

SO Infection and Immunity., (March, 2000) Vol. 68, No. 3, pp. 1655-1663. ISSN: 0019-9567.

DT Article

LA English

SL English

AB Lipopolysaccharides (LPS) are proinflammatory bacterial products implicated in the pathogenesis of gram-negative sepsis and septic shock. Polymyxin B (PMB), a cyclic, cationic peptide antibiotic, inhibits biological activities of LPS through high-affinity binding to

the lipid A moiety. Small synthetic peptides have been designed to mimic the primary and secondary structures of PMB to determine structural requirements for binding and detoxification of lipid A and to assess possible therapeutic potential. The purpose of this study was to compare and contrast the endotoxin-neutralizing activities of two synthetic antiendotoxin peptides (SAEP-2 and SAEP-4), PMB, and an LPS core-specific monoclonal antibody (MAb), WN1 222-5, based on their abilities to inhibit CD14-mediated target cell uptake of fluorescein isothiocyanate (FITC)-conjugated LPS, detected by flow cytometry and confocal

microscopy,

and LPS-induced production of the proinflammatory cytokines, interleukin-6

(IL-6) and tumor necrosis factor alpha (TNF-alpha), as measured by bioassays. PMB and SAEP-4 produced dose-dependent inhibition of FITC-LPS uptake by CD14-transfected Chinese hamster ovary fibroblasts (CHO-CD14 cells) and by human peripheral blood mononuclear cells. The anti-LPS MAb, WN1 222-5, also blocked LPS uptake by these cells and synergized with PMB and SAEP-4. LPS-induced IL-6 release was inhibited by PMB, SAEP-4, and MAb WN1 222-5, and these inhibitory activities were additive or synergistic. LPS-induced TNF-alpha release by PBMC was also inhibited by PMB and SAEP-4 alone and in combination with anti-LPS MAb. SAEP-2, in contrast, produced comparatively minor decrements in cellular uptake of LPS and LPS-induced cytokine responses, and did so only in the absence of serum, while a nonsense peptide exerted no discernible inhibitory effect on LPS uptake or LPS-induced cytokine expression in the presence or absence of serum. Thus, PMB and SAEP-4, like the LPS-reactive MAb, WN1 222-5, block proinflammatory activities of LPS in part by preventing LPS recognition by membrane-bound CD14-expressing target cells. Differences in peptide structure, however, like those exemplified by SAEP-2 and SAEP-4, may differentially affect the endotoxin-neutralizing potency of these peptides despite similar binding activity against lipid A, reflecting possible differences in peptide solubility or peptide regulation of intracellular signal transduction.

L3 ANSWER 3 OF 7 USPATFULL  
AN 97:66100 USPATFULL  
TI Peptides for neutralizing the toxicity of Lipid A  
IN Porro, Massimo, Siena, Italy  
PA BiosYnth S.r.l., Siena, Italy (non-U.S. corporation)  
PI US 5652211 19970729  
AI US 1993-97830 19930726 (8)  
RLI Continuation-in-part of Ser. No. US 1993-49871, filed on 19 Apr 1993, now patented, Pat. No. US 5358933 And Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented, Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned, said Ser. No. US -49871 which is a continuation of Ser. No. US -658744  
DT Utility  
EXNAM Primary Examiner: Russell, Jeffrey E.  
LREP Hedman, Gibson & Costigan, P.C.  
CLMN Number of Claims: 39  
ECL Exemplary Claim: 36,38  
DRWN No Drawings  
LN.CNT 683  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is concerned with a peptide composition which includes a peptide having units of the formula:

(a) (A).sub.n wherein A is Lysine or Arginine and n is an integer with a minimum value of 7.

(b) (AB).sub.m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a minimum value of 3; and

(c) (ABC).sub.p wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine,

L2 8 S L1 AND SEPSIS  
L3 7 DUP REM L2 (1 DUPLICATE REMOVED)

=> s l1 and lps (5a) peptide

L4 7 L1 AND LPS (5A) PEPTIDE

=> d bib 1-7

L4 ANSWER 1 OF 7 BIOSIS COPYRIGHT 2000 BIOSIS  
AN 2000:173998 BIOSIS  
DN PREV200000173998  
TI Influence of synthetic antiendotoxin peptides on Lipopolysaccharide (LPS) recognition and LPS-induced proinflammatory cytokine responses by cells expressing membrane-bound CD14.  
AU Iwagaki, Akitaka; Porro, Massimo; Pollack, Matthew (1)  
CS (1) Department of Medicine, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD, 20814 USA  
SO Infection and Immunity., (March, 2000) Vol. 68, No. 3, pp. 1655-1663. ISSN: 0019-9567.  
DT Article  
LA English  
SL English

L4 ANSWER 2 OF 7 USPATFULL  
AN 1998:138863 USPATFULL  
TI Potentiation of antibiotics  
IN Porro, Massimo, Siena, Italy  
Varra, Martti, Haartmaninkatu, Finland  
PA BiosYnth S.r.l., Italy (non-U.S. corporation)  
PI US 5834430 19981110  
AI US 1995-456112 19950531 (8)  
DT Utility  
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Harle, Jennifer  
LREP Hedman, Gibson & Costigan, P.C.  
CLMN Number of Claims: 45  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 951  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 7 USPATFULL  
AN 97:66100 USPATFULL  
TI Peptides for neutralizing the toxicity of Lipid A  
IN Porro, Massimo, Siena, Italy  
PA BiosYnth S.r.l., Siena, Italy (non-U.S. corporation)  
PI US 5652211 19970729  
AI US 1993-97830 19930726 (8)  
RLI Continuation-in-part of Ser. No. US 1993-49871, filed on 19 Apr 1993, now patented, Pat. No. US 5358933 And Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented, Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned, said Ser. No. US -49871 which is a continuation of Ser. No. US -658744  
DT Utility  
EXNAM Primary Examiner: Russell, Jeffrey E.  
LREP Hedman, Gibson & Costigan, P.C.  
CLMN Number of Claims: 39  
ECL Exemplary Claim: 36,38  
DRWN No Drawings  
LN.CNT 683

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 7 USPATFULL  
AN 96:120869 USPATFULL  
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock  
IN Porro, Massimo, Siena, Italy  
PA BiosYnth s.r.l., Siena, Italy (non-U.S. corporation)  
PI US 5589459 19961231  
AI US 1994-280397 19940726 (8)  
RLI Division of Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented,  
Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned  
DT Utility  
EXNAM Primary Examiner: Davenport, Avis M.  
LREP Hedman, Gibson & Costigan, P.C.  
CLMN Number of Claims: 14  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)  
LN.CNT 899

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 7 USPATFULL  
AN 94:106884 USPATFULL  
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock  
IN Porro, Massimo, Siena, Italy  
PA Biosynth S.r.l., Siena, Italy (non-U.S. corporation)  
PI US 5371186 19941206  
AI US 1992-819893 19920116 (7)  
DCD 20111025  
RLI Continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned  
DT Utility  
EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Davenport, A. M.  
LREP Hedman, Gibson & Costigan  
CLMN Number of Claims: 11  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)  
LN.CNT 852

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 7 USPATFULL  
AN 94:93312 USPATFULL  
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock  
IN Porro, Massimo, Siena, Italy  
PA BiosYnth S.r.l., Siena, Italy (non-U.S. corporation)  
PI US 5358933 19941025  
AI US 1993-49871 19930419 (8)  
RLI Continuation of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned  
DT Utility  
EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Marshall, S. G.  
LREP Hedman, Gibson & Costigan  
CLMN Number of Claims: 16  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 483

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2000 ACS  
AN 2000:146841 CAPLUS  
DN 132:303016



TI Influence of synthetic antiendotoxin peptides on lipopolysaccharide (LPS) recognition and LPS-induced proinflammatory cytokine responses by cells expressing membrane-bound CD14

AU Iwagaki, Akitaka; Porro, Massimo; Pollack, Matthew

CS Department of Medicine, Uniformed Services University of the Health Sciences, F. Edward Hebert School of Medicine, Bethesda, MD, 20814, USA

SO Infect. Immun. (2000), 68(3), 1655-1663  
CODEN: INFIBR; ISSN: 0019-9567

PB American Society for Microbiology

DT Journal

LA English

RE.CNT 38

RE

(1) Coyne, C; Am J Vet Res 1993, V54, P305 CAPLUS

(2) Demitri, M; J Endotoxin Res 1996, V3, P445 CAPLUS

(3) Di Padova, F; Infect Immun 1993, V61, P3863 CAPLUS

(4) Evans, T; J Infect Dis 1995, V171, P153 CAPLUS

(5) Golenbock, D; J Biol Chem 1993, V268, P22055 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s ll and gram negative bacterial infect?

L5 1 L1 AND GRAM NEGATIVE BACTERIAL INFECT?

=> d bib ab

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2000 ACS

AN 2000:84285 CAPLUS

DN 132:136410

TI Vaccines for prevention of **gram-negative bacterial infections** and endotoxin-related diseases

IN Porro, Massimo

PA Biosynth S.R.L., Italy

SO Eur. Pat. Appl., 40 pp.  
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 976402	A2	20000202	EP 1999-202476	19990727
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1998-124280		19980729		

AB A vaccine is disclosed which is useful for protecting a host from Gram neg. infections and the effects of endotoxin, therefore preventing sepsis and septic shock. The vaccine is prepd. by combining LPS free or in conjugate form with a stoichiometric excess of a peptide of the formula: (a) (A)<sub>n</sub> wherein A is Lysine or Arginine and n is an integer with a min. value of 7; (b) (AB)<sub>m</sub> wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a min. value of 3; and (c) (ABC)<sub>p</sub> wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a min. value of 2.

=> s bacterial (5a) infect?

L6 157699 BACTERIAL (5A) INFECT?

=> s 16 and lps (5a) peptide

L7 50 L6 AND LPS (5A) PEPTIDE

=> dup rem 17

PROCESSING COMPLETED FOR L7

L8 46 DUP REM L7 (4 DUPLICATES REMOVED)

=> d bib ab 1-46

L8 ANSWER 1 OF 46 USPATFULL

AN 2000:109964 USPATFULL

TI Antimicrobial peptides and methods of use thereof

IN Pereira, H. Anne, Edmond, OK, United States

PA The Board of Regents of the University of Oklahoma, Norman, OK, United States (U.S. corporation)

PI US 6107460 20000822

AI US 1999-258934 19990301 (9)

DT Utility

EXNAM Primary Examiner: Carlson, Karen Cochrane; Assistant Examiner: Srivastava, Deven

LREP Dunlap, Coddling & Rogers

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN 20 Drawing Figure(s); 20 Drawing Page(s)

LN.CNT 1073

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against **bacterial infections** and diseases caused by **bacterial infection**. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.

L8 ANSWER 2 OF 46 USPATFULL

AN 2000:106071 USPATFULL

TI Mammalian cationic proteins having lipopolysaccharide binding and anti-coagulant activity

IN Larrick, James W., Woodside, CA, United States

Wright, Susan C., Saratoga, CA, United States

Hirata, Michimasa, Morioka, Japan

PA Panorama Research, Inc., Mountain View, CA, United States (U.S. corporation)

PI US 6103888 20000815

AI US 1999-322911 19990601 (9)

RLI Continuation of Ser. No. US 1996-691280, filed on 1 Aug 1996 which is a continuation-in-part of Ser. No. US 313681

DT Utility

EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Portner, Ginny Allen

LREP Townsend and Townsend and Crew

CLMN Number of Claims: 1

ECL Exemplary Claim: 1

DRWN 30 Drawing Figure(s); 20 Drawing Page(s)

LN.CNT 1944

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the treatment and diagnosis of lipopolysaccharide-related conditions and coagulant-related disease are provided. Compositions include polypeptides which are identical or homologous to a certain cationic protein (CAP18) obtained from mammalian

granulocytes, particularly including a reactive nitrogen inhibiting

peptide (RNIP) fragment found at the carboxy-terminus of CAP18. Polypeptides are capable of binding to LPS and inhibiting LPS-mediated activation of macrophage, as well as interfering with the clotting cascade to inhibit coagulation in conditions such as disseminated intravascular coagulation. Compositions comprising the polypeptides in

a

suitable pharmaceutical carrier are also provided.

L8 ANSWER 3 OF 46 USPATFULL  
AN 2000:70809 USPATFULL  
TI Method for the treatment of **bacterial infection**  
IN Pereira, Heloise Anne, Edmond, OK, United States  
PA The Board of Regents of the University of Oklahoma, United States (U.S. corporation)  
PI US 6071879 20000606  
AI US 1999-260373 19990301 (9)  
RLI Continuation of Ser. No. US 1997-840519, filed on 21 Apr 1997, now patented, Pat. No. US 5877151 which is a continuation of Ser. No. US 1995-482328, filed on 7 Jun 1995, now patented, Pat. No. US 5627262, issued on 6 May 1997 which is a continuation-in-part of Ser. No. US 1994-235399, filed on 29 Apr 1994, now patented, Pat. No. US 5607916 which is a continuation-in-part of Ser. No. US 1992-969931, filed on 30 Oct 1992, now patented, Pat. No. US 5458874 which is a continuation of Ser. No. US 1992-855417, filed on 19 Mar 1992, now patented, Pat. No. US 5484885 which is a continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-375739, filed on 5 Jul 1989, now abandoned  
DT Utility  
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Moore, William W.  
LREP Dunlap, Coddling & Rogers, P.C.  
CLMN Number of Claims: 3  
ECL Exemplary Claim: 1  
DRWN 19 Drawing Figure(s); 19 Drawing Page(s)  
LN.CNT 806  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention contemplates a composition and method for treating  
a **bacterial infection** in a mammal.  
Comprising/administering a therapeutically effective amount of a peptide  
derived from CAP37 protein. In a preferred version, the composition and method of use may comprise a peptide comprising amino acids 20-44 or 120-146 of CAP37 or subunits thereof.

L8 ANSWER 4 OF 46 USPATFULL  
AN 2000:54074 USPATFULL  
TI Antimicrobial cationic peptides  
IN Hancock, Robert E. W., Vancouver, Canada  
Karunaratne, Nedra, Kandy, Sri Lanka  
PA University of British Columbia, Vancouver, Canada (non-U.S. corporation)  
PI US 6057291 20000502  
AI US 1996-763226 19961210 (8)  
RLI Continuation-in-part of Ser. No. US 1996-658857, filed on 31 May 1996 which is a continuation-in-part of Ser. No. US 1995-460464, filed on 2 Jun 1995, now patented, Pat. No. US 5877274  
DT Utility  
EXNAM Primary Examiner: Prouty, Rebecca E.; Assistant Examiner: Longton, Enrique D.  
LREP Fish & Richardson P. C.  
CLMN Number of Claims: 10  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)

LN.CNT 2740

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH.sub.2  
--KWKSFIKKLTAVKKVLTGLPALIS--COOH (SEQ ID NO:1) and NH.sub.2  
--KWKSFIKKLTSAAKKVVTAKPLISS--COOH (SEQ ID NO:2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.

L8 ANSWER 5 OF 46 USPATFULL

AN 2000:34679 USPATFULL

TI Antimicrobial cationic peptides

IN Hancock, Robert E. W., Vancouver, Canada

Karunaratne, Nedra, Vancouver, Canada

PA University of British Columbia, Vancouver, Canada (non-U.S. corporation)

PI US 6040435 20000321

AI US 1996-658857 19960531 (8)

RLI Continuation-in-part of Ser. No. US 1995-460464, filed on 2 Jun 1995, now patented, Pat. No. US 5877274

DT Utility

EXNAM Primary Examiner: Sisson, Bradley; Assistant Examiner: Longton, Enrique D.

LREP Gary Cary Ware & Freidenrich LLP; Haile, Lisa A.

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN 12 Drawing Figure(s); 9 Drawing Page(s)

LN.CNT 2069

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include

NH.sub.2 -KWKSFIKKLTAVKKVLTGLPALIS-COOH (SEQ ID  
NO:1)

and

NH.sub.2 -KWKSFIKKLTSAAKKVVTAKPLISS-COOH. (SEQ ID  
NO:2)

Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.

L8 ANSWER 6 OF 46 USPATFULL

AN 2000:34537 USPATFULL

TI Antimicrobial peptide

IN Hirata, Michimasa, Morioka, Japan

PA Seikagaku Corporation, Tokyo, Japan (non-U.S. corporation)

PI US 6040291 20000321

AI US 1999-276202 19990325 (9)

PRAI JP 1998-78136 19980325

JP 1998-176466 19980623

DT Utility

EXNAM Primary Examiner: Russel, Jeffrey E.

LREP Knobbe, Martens, Olson & Bear, LLP

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN 8 Drawing Figure(s); 6 Drawing Page(s)

LN.CNT 1558

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A peptide comprising at least the following amino acid sequence:

Lys Xa1 Phe Lys Arg Ile Val Xa2 Arg Ile Xaa Xa2 Phe Leu Arg Xa2 Leu Val  
(SEQ ID NO: 1)

wherein, Xa1 represents a hydrophobic amino acid residue, each of Xa2 independently represents a hydrophilic amino acid residue, and Xaa represents an arbitrary amino acid residue;

an antimicrobial agent, a medicine including a **bacterial infection**-treating agent and an endotoxin shock suppressant which each comprise the peptide as an active ingredient; and an endotoxin-removing agent comprising the peptide immobilized to an insoluble carrier.

L8 ANSWER 7 OF 46 USPATFULL  
AN 2000:1857 USPATFULL  
TI Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis  
IN Andersen, Anders Jorgen, Kokkedal, Denmark  
Aston, Roger, Wiltshire, United Kingdom  
Carlen, Peter Louis, Ontario, Canada  
Doob, Penelope Reed, Ontario, Canada  
MacFadden, Douglas Kevin, Ontario, Canada  
Phipps, David James, Ontario, Canada  
Rathjen, Deborah, New South Wales, Australia  
Widmer, Fred, New South Wales, Australia  
PA Advanced Immunit, Inc., Stony Brook, NY, United States (U.S. corporation)  
PI US 6011014 20000104  
AI US 1998-82837 19980521 (9)  
RLI Continuation of Ser. No. US 302829  
DT Utility  
EXNAM Primary Examiner: Davenport, Avis M.  
LREP Nims, Howes, Collison Hansen & Lackert  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN 15 Drawing Figure(s); 9 Drawing Page(s)  
LN.CNT 2387  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB A method of treating or preventing multiple sclerosis in a patients in need of such treatment by administering an effect amount of the peptide:  
I-A-B-C-D-E-F-G-H-II (General Formula) wherein A is Ala, Gly, Val, Ser, Thr or absent, B is Ala, Gly, Val, Ser, Thr or absent, C is Ser, Thr or absent, D is Ser, Thr, Asn, Glu, Arg, Ile, Leu or absent, E is Ser, Thr,  
Asp or absent, F is Thr, Ser, Asn, Glu, Lys, Trp or absent, G is tyr or absent; H is Thr, Arg, Gly, Met, Met(O), Gys, Thr, Gly or absent, I is Cys or absent, II is Cys, an amide group, substituted amide group, an ester group or absent.

L8 ANSWER 8 OF 46 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD  
AN 2000-128304 [12] WPIDS  
DNC C2000-039402  
TI New vaccine for prevention of gram-negative **bacterial infections** and endotoxin related disorders, comprises complex of **peptide** and **LPS**.  
DC B04 B05 D16  
IN PORRO, M  
PA (BIOS-N) BIOSYNTH SRL  
CYC 26  
PI EP 976402 A2 20000202 (200012)\* EN 43p  
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI  
CA 2279316 A1 20000129 (200028) EN  
ADT EP 976402 A2 EP 1999-202476 19990727; CA 2279316 A1 CA 1999-2279316 19990729  
PRAI US 1998-124280 19980729

AB EP 976402 A UPAB: 20000308  
 NOVELTY - A vaccine for preventing gram negative infections and the effects of endotoxins is new and comprises a complex obtained by combining LPS free or in conjugate form with a sufficient amount of a peptide which is capable of producing a non-toxic, highly immunogenic complex.

DETAILED DESCRIPTION - A vaccine for preventing gram negative infections and the effects of endotoxins is new and comprises a complex obtained by combining LPS free or in conjugate form with a sufficient amount of a peptide which is capable of producing a non-toxic, highly immunogenic complex. The peptide is of the formula (a) - (c):

(a) (A)n;  
 (b) (AB)m; and/or  
 (c) (ABC)p.

A = a cationic amino acid e.g. Lysine or Arginine;  
 B = a hydrophobic amino acid e.g. Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan;  
 C = a hydrophobic amino acid e.g. Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan;  
 n = integer of 7-16;  
 m = integer of 4-20;  
 p = integer of 4-20.

An INDEPENDENT CLAIM is also included for a method for the preparation of a vaccine for prevention of gram-negative infections and the effects of endotoxins.

ACTIVITY - Antibacterial.  
 No relevant activity data given.

MECHANISM OF ACTION - The excess **peptide** significantly stabilizes the **LPS peptide** complex from the likely antagonistic activity of natural LPS-receptor proteins present on specialized cells of the immune system.

USE - The vaccine is useful for the prevention of **bacterial infections** caused by gram-negative bacteria and for the prevention of biological effects of homologous endotoxins, especially for preventing sepsis and septic shock.

ADVANTAGE - The toxic characteristic of LPS may be removed without eliminating the antigenic and immunogenic properties of LPS by binding the LPS (via the lipid A moiety) to a peptide.

Dwg.0/0

L8 ANSWER 9 OF 46 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.DUPLICATE 1  
 AN 2000255567 EMBASE  
 TI A Limulus antilipopolysaccharide factor-derived peptide exhibits a new immunological activity with potential applicability in infectious diseases.  
 AU Vallespi M.G.; Glaria L.A.; Reyes O.; Garay H.E.; Ferrero J.; Arana M.J.  
 CS M.G. Vallespi, Division of Cellular Biology, Center for Biological Research, Calle 134 e/Ave. 25 y 23, Cubanacan, Havana, Cuba.  
 maribel.guerra@cigb.edu.cu  
 SO Clinical and Diagnostic Laboratory Immunology, (2000) 7/4 (669-675).  
 Refs: 51  
 ISSN: 1071-412X CODEN: CDIMEN  
 CY United States  
 DT Journal; Article  
 FS 026 Immunology, Serology and Transplantation  
 030 Pharmacology  
 037 Drug Literature Index  
 LA English  
 SL English  
 AB Previous studies have shown that cyclic peptides corresponding to residues 35 to 52 of the Limulus antilipopolysaccharide (anti-LPS) factor (LALF) bind and neutralize LPS-mediated in vitro and in vivo activities. Therapeutic approaches based on agents which bind and neutralize LPS

activities are particularly attractive because these substances directly block the primary stimulus for the entire proinflammatory cytokine cascade. Here we describe new activities of the LALF31-52 **peptide**, other than its **LPS** binding ability. Surprisingly, supernatants from human mononuclear cells stimulated with the LALF peptide are able to induce in vitro antiviral effects on the Hep-2 cell line mediated by

gamma

interferon (IFN-.gamma.) and IFN- .alpha.. Analysis of the effect of LALF31-52 on tumor necrosis factor (TNF) and nitric oxide (NO) production by LPS-stimulated peritoneal macrophages revealed that a pretreatment

with

the **peptide** decreased **LPS**-induced TNF production but did not affect NO generation. This indicates that the LALF **peptide** modifies the **LPS**-induced response. In a model in mice with peritoneal fulminating sepsis, LALF31-52 protected the mice when administered prophylactically, and this effect is related to reduced systemic TNF-.alpha. levels. This study demonstrates, for the first time, the anti-inflammatory properties of the LALF-derived peptide. These properties widen the spectrum of the therapeutic potential for this LALF-derived peptide and the molecules derived from it. These agents may be useful in the prophylaxis and therapy of viral and **bacterial infectious** diseases, as well as for septic shock.

L8 ANSWER 10 OF 46 USPATFULL

AN 1999:40567 USPATFULL

TI Porphenins--antibiotic peptides

IN Kokryakov, Vladimir N., Los Angeles, CA, United States

Harwig, Sylvia S.L., Woodland Hills, CA, United States

Lehrer, Robert I., Santa Monica, CA, United States

PA Regents of the University of California, Oakland, CA, United States  
(U.S. corporation)

PI US 5889152 19990330

AI US 1995-477131 19950607 (8)

RLI Division of Ser. No. US 1994-222798, filed on 5 Apr 1994

DT Utility

EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Lau, Kawai

LREP Morrison & Foerster

CLMN Number of Claims: 6

ECL Exemplary Claim: 1

DRWN 6 Drawing Figure(s); 4 Drawing Page(s)

LN.CNT 1053

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Peptide-based compounds containing multiple proline residues are useful as preservatives and in preventing, treating, or ameliorating microbial **infection**, especially Gram-negative **bacterial infection** in animals and plants, in treating conditions characterized by the presence of **LPS**. These compounds are of the

formula

##STR1## including the N-terminal acylated and/or C-terminal amidated

or

esterified forms thereof

wherein each of A.sub.1, A.sub.5, A.sub.10, A.sub.14 and A.sub.20 is independently Ala, Gly or Ser;

each of A.sub.2, A.sub.4, A.sub.7, A.sub.9, A.sub.11, A.sub.12, A.sub.13, A.sub.16, A.sub.17, A.sub.19 and A.sub.22 is independently a hydrophobic amino acid selected from the group consisting of Ile, Leu, Val, Phe and Met;

each of A.sub.3 and A.sub.8 is independently a neutral polar amino acid selected from Asn and Gln or is a hydrophobic amino acid selected from the group consisting of Ile, Leu, Val, Phe and Met;

each of A.sub.6, A.sub.18 and A.sub.21 is independently a basic amino

acid selected from Arg, Lys, and Har; and

wherein A.sub.15 is Trp or a basic amino acid selected from Lys, Arg and Har;

wherein n is an integer of 1-6; and

the antimicrobial or LPS-binding fragments thereof. Recombinant materials for the production of these peptides are also disclosed.

L8 ANSWER 11 OF 46 USPATFULL  
AN 1999:27732 USPATFULL  
TI Antimicrobial cationic peptides  
IN Hancock, Robert E. W., Vancouver, Canada  
Karunaratne, Nedra, Vancouver, Canada  
PA University of British Columbia, Vancouver, Canada (non-U.S. corporation)  
PI US 5877274 19990302  
AI US 1995-460464 19950602 (8)  
DT Utility  
EXNAM Primary Examiner: Carlson, Karen Cochrane; Assistant Examiner: Longton, Enrique D.  
LREP Fish & Richardson P.C.  
CLMN Number of Claims: 2  
ECL Exemplary Claim: 1  
DRWN 10 Drawing Figure(s); 10 Drawing Page(s)  
LN.CNT 1008  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH.sub.2  
-KWKSFIKKLTAVKKVLTGTPALIS-COOH (SEQ ID NO:1) and NH.sub.2  
-KWKSFIKKLTSAKKVVTTAKPLISS-COOH (SEQ ID NO:2).

L8 ANSWER 12 OF 46 USPATFULL  
AN 1999:27610 USPATFULL  
TI Method for inhibiting production of tumor necrosis factor  
IN Pereira, Heloise Anne, Edmond, OK, United States  
PA The Board of Regents of the University of Oklahoma, United States (U.S. corporation)  
PI US 5877151 19990302  
AI US 1997-840519 19970421 (8)  
RLI Continuation of Ser. No. US 1995-482328, filed on 7 Jun 1995, now patented, Pat. No. US 5627262, issued on 6 May 1997 which is a continuation-in-part of Ser. No. US 1994-235399, filed on 29 Apr 1994, now patented, Pat. No. US 5607916, issued on 4 Mar 1997 which is a continuation-in-part of Ser. No. US 1992-939931, filed on 30 Oct 1992, now patented, Pat. No. US 5458874, issued on 17 Oct 1995 which is a continuation of Ser. No. US 1992-855417, filed on 19 Mar 1992, now patented, Pat. No. US 5484885, issued on 16 Jan 1996 which is a continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-375739, filed on 5 Jul 1989, now abandoned  
DT Utility  
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Moore, William W.  
LREP Dunlap & Coddington, P.C.  
CLMN Number of Claims: 2  
ECL Exemplary Claim: 1  
DRWN 19 Drawing Figure(s); 19 Drawing Page(s)  
LN.CNT 804  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention contemplates a composition and method for treating  
septic shock in a mammal or as a prophylactic treatment prior to a surgical procedure, comprising administering a therapeutically effective



amount of a bacterial lipopolysaccharide binding peptide derived from CAP37 protein. In a preferred version, the composition and method of use may comprise a peptide comprising amino acids 20-44 or 120-146 of CAP37 or subunits thereof.

L8 ANSWER 13 OF 46 USPATFULL  
AN 1999:4632 USPATFULL  
TI Anti-fungal peptides  
IN Little, II, Roger G., Benicia, CA, United States  
Lim, Edward, Walnut Creek, CA, United States  
Fadem, Mitchell B., Carmel Valley, CA, United States  
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)  
PI US 5858974 19990112  
AI US 1996-621259 19960321 (8)  
RLI Continuation-in-part of Ser. No. US 1995-504841, filed on 20 Jul 1995  
DT Utility  
EXNAM Primary Examiner: Davenport, Avis M.  
LREP McAndrews, Held & Malloy, Ltd.  
CLMN Number of Claims: 15  
ECL Exemplary Claim: 1  
DRWN 10 Drawing Figure(s); 10 Drawing Page(s)  
LN.CNT 5315

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates generally to anti-fungal peptides derived from or based on Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI) and in vivo or in vitro uses of such peptides.

L8 ANSWER 14 OF 46 USPATFULL  
AN 1999:1767 USPATFULL  
TI Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof  
IN Little, II, Roger G., Benicia, CA, United States  
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)  
PI US 5856438 19990105  
AI US 1995-485445 19950607 (8)  
RLI Continuation of Ser. No. US 1994-306473, filed on 15 Sep 1994, now patented, Pat. No. US 5652332 And a continuation-in-part of Ser. No. US 1994-273540, filed on 11 Jul 1994, now abandoned And Ser. No. US 1994-274299, filed on 11 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-209762, filed on 11 Mar 1994, now patented, Pat. No. US 5696085 which is a continuation-in-part of Ser. No. US 1994-183222, filed on 14 Jan 1994, now abandoned , said

Ser. No. US 306473 which is a continuation-in-part of Ser. No. US 209762 , said Ser. No. US 183222 which is a continuation-in-part of Ser. No. US 1993-93202, filed on 15 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-30644, filed on 12 Mar 1993, now patented, Pat. No. US 5348942  
DT Utility  
EXNAM Primary Examiner: Davenport, Avis M.  
LREP McAndrews, Held & Malloy, Ltd.  
CLMN Number of Claims: 11  
ECL Exemplary Claim: 1  
DRWN 94 Drawing Figure(s); 78 Drawing Page(s)  
LN.CNT 5756

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof,

and variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal

activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.

L8 ANSWER 15 OF 46 JAPIO COPYRIGHT 2000 JPO  
AN 1999-335396 JAPIO  
TI NEW ANTIMICROBIAL PEPTIDE  
IN HIRATA RIKUMASA  
PA SEIKAGAKU KOGYO CO LTD  
PI JP 11335396 A 19991207 Heisei  
AI JP1998-176466 (JP10176466 Heisei) 19980623  
PRAI JP 1998-78136 19980325  
SO PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined Applications, Vol. 99  
AB PROBLEM TO BE SOLVED: To obtain a new antimicrobial peptide consisting of a human-derived peptide having a specific amino acid sequence, having lipopolysaccharide(LPS) binding activity, excellent in antimicrobial activity and LPS-neutralizing activity, and useful as an antimicrobial agent, endotoxin removing agent or the like.  
SOLUTION: This new peptide is such one as to contain at least an amino acid sequence of the formula and have lipopolysaccharide(LPS) binding activity, antimicrobial activity and LPS-neutralizing activity, being useful as an antimicrobial agent, therapeutic agent for **bacterial infectious** diseases, endotoxin shock inhibitor, endotoxin removing agent or the like. This new peptide is obtained by designing an amino acid sequence constructing a **peptide** with antimicrobial activity, **LPS** binding activity and LPS-neutralizing activity raised through the change in the balance between the hydrophilic portion and hydrophobic portion as a result of substituting the amino acid residue at a specific site on a partial **peptide** of the **LPS**-bound domain of human-derived CAP18 by another specific amino acid residue, and by chemically synthesizing the above peptide with peptide solid phase synthesis or the like.  
COPYRIGHT: (C)1999,JPO

L8 ANSWER 16 OF 46 CAPLUS COPYRIGHT 2000 ACS  
AN 2000:15169 CAPLUS  
DN 132:333324  
TI "Designer" peptides derived from bactericidal/permeability-increasing protein recapitulate its endotoxin binding region  
AU Weiss, Carl A., III; Wasiluk, Karen R.; Kellogg, Todd A.; Gray, Beulah H.; Mayo, Kevin H.; Dunn, David L.  
CS Department of Surgery, University of Minnesota, Minneapolis, MN, USA  
SO Surg. Forum (1999), 50, 217-219  
CODEN: SUFOAX; ISSN: 0071-8041  
PB American College of Surgeons  
DT Journal  
LA English  
AB A synthetic 27-amino acid peptide of bactericidal/permeability-increasing protein is bactericidal toward Pseudomonas aeruginosa and abrogates LPS-induced TNF-.alpha. release from macrophages in vitro, but this activity diminishes in vivo. We hypothesized that BPI-derived peptides designed to recapitulate the native secondary structure of the active domain (amphipathic .beta.-turn) would exhibit more potent anti-LPS activity than unmodified peptides during murine endotoxemia and would be useful adjunctive reagents for the treatment of serious gram-neg. **bacterial infection** and sepsis. The results show that modified BPI-derived **peptide** inhibited **LPS**-induced TNF-.alpha. and is a promising agent in treatment of gram-neg. **bacterial infection** and sepsis.

RE.CNT 13

RE

- (1) Abello, P; Free Radicals in Diagnostic Medicine 1994, P253 CAPLUS
- (2) Appelmek, B; Infect Immun 1994, V62, P3564 CAPLUS
- (4) Beamer, L; Science V276, P1861 CAPLUS

(6) Dentener, M; J Immunol 1993, V151, P4258 CAPLUS  
(7) Fenton, M; J Leukocyte Biol 1998, V64, P25 CAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 17 OF 46 USPATFULL  
AN 1998:135009 USPATFULL  
TI Peptides with bactericidal activity and endotoxin neutralizing activity  
for gram negative bacteria and methods for their use  
IN Gray, Beulah H., St. Paul, MN, United States  
Haseman, Judith R., Eagan, MN, United States  
Mayo, Kevin H., Minnetonka, MN, United States  
PA Regents of the University of Minnesota, Minneapolis, MN, United States  
(U.S. corporation)  
PI US 5830860 19981103  
AI US 1996-653632 19960524 (8)  
RLI Continuation-in-part of Ser. No. US 1994-218026, filed on 24 Mar 1994  
DT Utility  
EXNAM Primary Examiner: Patterson, Jr., Charles L.  
LREP Merchant, Gould, Smith, Edell & Welter  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN 8 Drawing Figure(s); 7 Drawing Page(s)  
LN.CNT 3162

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides biologically active peptides derived from or  
corresponding to regions of a bactericidal permeability increasing  
factor (B/PI). The peptides are preferably about 10 to 100 amino acids  
long and have bactericidal and/or endotoxin neutralizing activity. The  
peptides can be prepared by automated protein synthesis or by  
recombinant DNA methods. The peptides are useful in methods to treat

and  
prevent **bacterial infection** in the body and on  
surfaces. The peptides are also useful to treat endotoxin shock and

have  
endotoxin neutralizing activity.

L8 ANSWER 18 OF 46 USPATFULL  
AN 1998:108385 USPATFULL  
TI Prophenins - antibiotic peptides  
IN Kokryakov, Vladimir N., Los Angeles, CA, United States  
Harwig, Sylvia S. L., Woodland Hills, CA, United States  
Lehrer, Robert I., Santa Monica, CA, United States  
PA University of California, Los Angeles, CA, United States (U.S.  
corporation)  
PI US 5804553 19980908  
AI US 1994-222798 19940405 (8)  
DT Utility  
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Lau, Kawai  
LREP Morrison & Foerster LLP  
CLMN Number of Claims: 6  
ECL Exemplary Claim: 1  
DRWN 6 Drawing Figure(s); 4 Drawing Page(s)  
LN.CNT 1008

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Peptide-based compounds containing multiple proline residues are useful  
as preservatives and in preventing, treating, or ameliorating microbial  
**infection**, especially Gram-negative **bacterial**  
**infection** in animals and plants, in treating conditions  
characterized by the presence of LPS. These compounds are of the

formula  
##STR1## including the N-terminal acylated and/or C-terminal amidated  
or  
esterified forms thereof

wherein each of A.sub.1, A.sub.5, A.sub.10, A.sub.14 and A.sub.20 is

independently Ala, Gly or Ser;

each of A.sub.2, A.sub.4, A.sub.7, A.sub.9, A.sub.11, A.sub.12, A.sub.13, A.sub.16, A.sub.17, A.sub.19 and A.sub.22 is independently a hydrophobic amino acid selected from the group consisting of Ile, Leu, Val, Phe and Met;

each of A.sub.3 and A.sub.8 is independently a neutral polar amino acid selected from Asn and Gln or is a hydrophobic amino acid selected from the group consisting of Ile, Leu, Val, Phe and Met;

each of A.sub.6, A.sub.18 and A.sub.21 is independently a basic amino acid selected from Arg, Lys, and Har; and

and wherein A.sub.15 is Trp or a basic amino acid selected from Lys, Arg Har;

wherein n is an integer of 1-6; and

the antimicrobial or LPS-binding fragments thereof. Recombinant materials for the production of these peptides are also disclosed.

L8 ANSWER 19 OF 46 USPATFULL

AN 1998:92001 USPATFULL

TI Treatment of endotoxin-associated disorders with cationic peptides

IN Hancock, Robert E. W., Vancouver, Canada

Piers, Kevin L., Richmond, Canada

Brown, Melissa H., Vancouver, Canada

Kelly, Niamh, Vancouver, Canada

PA University of British Columbia, Vancouver, Canada (non-U.S. corporation)

PI US 5789377 19980804

AI US 1995-405234 19950313 (8)

RLI Continuation-in-part of Ser. No. US 1993-110502, filed on 20 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-933492, filed on 21 Aug 1992, now abandoned

DT Utility

EXNAM Primary Examiner: Patterson, Jr., Charles L.

LREP Fish & Richardson, P.C.

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN 24 Drawing Figure(s); 17 Drawing Page(s)

LN.CNT 1454

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for the microbial production of a cationic peptide having anti-microbial activity is provided, wherein the cationic peptide is first produced as a fusion protein having an anionic portion for suppressing the antimicrobial activity of the cationic portion. A novel cationic **peptide** having anti-microbial activity and **LPS-binding** activity is also provided. Such peptides are useful for suppressing the growth of bacteria and for the treatment of endotoxemia-associated disorders.

L8 ANSWER 20 OF 46 USPATFULL

AN 1998:88809 USPATFULL

TI Synthetic peptides with bactericidal activity and endotoxin neutralizing

activity for gram negative bacteria and methods for their use

IN Gray, Beulah, St. Paul, MN, United States

Haseman, Judith R., Eagan, MN, United States

Mayo, Kevin, Minnetonka, MN, United States

PA Regents of the University of Minnesota, Minneapolis, MN, United States (U.S. corporation)

PI US 5786324 19980728

AI US 1994-218026 19940324 (8)  
DT Utility  
EXNAM Primary Examiner: Patterson, Jr., Charles L.  
LREP Merchant, Gould, Smith, Edell, Welter & Schmidt  
CLMN Number of Claims: 27  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Figure(s); 10 Drawing Page(s)  
LN.CNT 2603

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides biologically active peptides derived from or corresponding to regions of a bactericidal permeability increasing factor (B/PI). The peptides are about 10 to 100 amino acids long and have bactericidal and/or endotoxin neutralizing activity. The peptides can be prepared by automated DNA synthesis or by recombinant DNA methods. The peptides are useful in methods to treat and prevent **bacterial infection** in the body and on surfaces. The peptides are also useful to treat endotoxin shock.

L8 ANSWER 21 OF 46 USPATFULL

AN 1998:65346 USPATFULL

TI Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof

IN Little, Roger G., Benicia, CA, United States

PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)

PI US 5763567 19980609

AI US 1995-473344 19950607 (8)

RLI Continuation of Ser. No. US 1994-209762, filed on 11 Mar 1994 which is a

continuation-in-part of Ser. No. US 1994-183222, filed on 14 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93202,

filed on 15 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-30644, filed on 12 Mar 1993, now patented, Pat. No. US 5348942

DT Utility

EXNAM Primary Examiner: Carlson, Karen C.

LREP McAndrews, Held & Malloy, Ltd.

CLMN Number of Claims: 7

ECL Exemplary Claim: 1

DRWN 86 Drawing Figure(s); 70 Drawing Page(s)

LN.CNT 3868

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and

variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.

L8 ANSWER 22 OF 46 USPATFULL

AN 1998:57873 USPATFULL

TI Peptide T and related peptides in the treatment of inflammation, including inflammatory bowel disease

IN Andersen, Anders Jorgen, Kokkedal, Denmark

Aston, Roger, Wiltshire, England

Carlen, Peter Louis, Ontario, Canada

Doob, Penelope Reed, Ontario, Canada

MacFadden, Douglas Kevin, Ontario, Canada

Phipps, David James, Ontario, Canada

Rathjen, Deborah, New South Wales, Australia

Widmer, Fred, New South Wales, Australia

PA Peptide Technology Limited, Dee Why, Australia (non-U.S. corporation)

Drug Royalty Corporation, New South Wales, Australia (non-U.S. corporation)

PI US 5756449 19980526  
WO 9320102 19931014

AI US 1995-302829 19950224 (8)  
WO 1993-GB649 19930329  
19950224 PCT 371 date  
19950224 PCT 102(e) date

PRAI DK 1992-645 19920514

DT Utility

EXNAM Primary Examiner: Cain, Edward J.

LREP Banner & Witcoff, Ltd.

CLMN Number of Claims: 18

ECL Exemplary Claim: 1

DRWN 17 Drawing Figure(s); 9 Drawing Page(s)

LN.CNT 2365

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating inflammatory bowel disease in patients in need of such treatment by administering an effective amount of:  
I-A-B-C-D-E-F-G-H-II (General Formula I), wherein A is Ala, Gly, Val, Ser, Thr or absent, B is Ala, Gly, Val, Ser, Thr, or absent, C is Ser, Thr or absent, D is Ser, Thr, Asn, Glu, Arg, Ile, Leu or absent, E is Ser, Thr, Asp or absent, F is Ser, Thr, Asp or absent, G is Tyr or absent, H is Thr, Arg, Gly, Met, Met(O), Cys, Thr, Gly or absent, and I is Cys or absent II is Cys, an amide group, substituted amid group, an ester group or absent. At least one of the amino acids optionally being substituted by a monomeric or polymeric carbohydrate or derivative thereof, such substitution being accomplished through hydroxyl and/or amino and/or amido groups of the amino acids, and wherein the peptide comprises at least 4 amino acid residues, and a pharmaceutically acceptable salt thereof.

L8 ANSWER 23 OF 46 USPATFULL

AN 1998:36361 USPATFULL

TI Alteration of immune response using pan DR-binding peptides

IN Sette, Alessandro, La Jolla, CA, United States  
Gaeta, Federico, Foster City, CA, United States  
Grey, Howard M., La Jolla, CA, United States  
Sidney, John, La Jolla, CA, United States  
Alexander, Jeffrey L., Encinita, CA, United States

PA Cytel Corporation, San Diego, CA, United States (U.S. corporation)

PI US 5736142 19980407

AI US 1994-305871 19940914 (8)

RLI Continuation-in-part of Ser. No. US 1993-121101, filed on 14 Sep 1993, now abandoned

DT Utility

EXNAM Primary Examiner: Cunningham, Thomas M.

LREP Townsend and Townsend and Crew LLP

CLMN Number of Claims: 56

ECL Exemplary Claim: 1

DRWN 14 Drawing Figure(s); 4 Drawing Page(s)

LN.CNT 2085

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and methods of inhibiting or  
inducing activation of T cells in a patient. The methods comprise administering a therapeutically effective dose of pharmaceutical compositions comprising a pharmaceutically acceptable carrier and peptides of between about 4 and about 20 residues, that bind antigen binding sites on MHC molecules encoded by substantially all alleles of  
a  
DR locus. These peptides are referred to as pan DR binding peptides.  
The  
pan DR binding peptides can be used to inhibit immune responses associated with immunopathologies, such as autoimmunity, allograft

rejection and allergic responses. The peptides can also be used in combination with CTL peptides to enhance a CTL response.

L8 ANSWER 24 OF 46 USPATFULL  
AN 1998:33895 USPATFULL  
TI Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof  
IN Little, Roger G., Benicia, CA, United States  
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)  
PI US 5733872 19980331  
AI US 1994-209762 19940311 (8)  
RLI Continuation-in-part of Ser. No. US 1994-183222, filed on 14 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93202, filed on 15 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-30644, filed on 12 Mar 1993, now patented, Pat. No. US 5348942  
DT Utility  
EXNAM Primary Examiner: Carlson, Karen C.  
LREP McAndrews, Held & Malloy, Ltd.  
CLMN Number of Claims: 45  
ECL Exemplary Claim: 1  
DRWN 86 Drawing Figure(s); 70 Drawing Page(s)  
LN.CNT 3967  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.

L8 ANSWER 25 OF 46 USPATFULL  
AN 1998:25345 USPATFULL  
TI Immuno-potentiating systems for preparation of immunogenic materials  
IN Lowell, George H., 6303 Westlin Run Dr., Baltimore, MD, United States 21215  
PI US 5726292 19980310  
AI US 1993-143365 19931029 (8)  
RLI Continuation-in-part of Ser. No. US 1993-29666, filed on 11 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1989-336952, filed on 12 Apr 1989, now abandoned And a continuation-in-part of Ser. No. US 1991-642093, filed on 16 Jan 1991, now abandoned which is a continuation of Ser. No. US 1987-65440, filed on 23 Jun 1987, now abandoned  
DT Utility  
EXNAM Primary Examiner: Budens, Robert D.  
LREP Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro LLP  
CLMN Number of Claims: 15  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1228  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention is directed to improved immunopotentiating systems for preparation of immunogenic materials. More particularly, the invention is directed to immunogenic compositions containing a protein, polypeptide, or peptide, a hydrophobic anchor, and a proteosome. The immunogenic compositions are suitable for use as therapeutic agents and vaccines.

L8 ANSWER 26 OF 46 USPATFULL  
AN 1998:1683 USPATFULL

TI Methods for identifying inhibitors of LPS-mediated LBP binding  
IN Mintz, Douglas N., New York, NY, United States  
Tobias, Peter, San Diego, CA, United States  
Ulevitch, Richard, Del Mar, CA, United States  
PA The Scripps Research Institute, La Jolla, CA, United States (U.S.  
corporation)  
PI US 5705398 19980106  
AI US 1994-205719 19940302 (8)  
DT Utility  
EXNAM Primary Examiner: Allen, Marianne P.; Assistant Examiner: Duffy,  
Patricia A.  
LREP Fitting, Thomas; Holmes, Emily  
CLMN Number of Claims: 12  
ECL Exemplary Claim: 1  
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)  
LN.CNT 1313  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention describes a rapid method for the identification  
of  
LPS compounds/reagents which inhibit lipopolysaccharide (LPS) binding to  
binding protein (LBP), and kits for practicing the method.

L8 ANSWER 27 OF 46 USPATFULL  
AN 97:107054 USPATFULL  
TI Treatment of endotoxin-associated disorders with cationic peptides  
IN Hancock, Robert E. W., Vancouver, Canada  
Piers, Kevin L., Red Deer, Canada  
Brown, Melissa H., Canterbury, Australia  
Kelly, Niamh, Vancouver, Canada  
PA University of British Columbia, Vancouver, Canada (non-U.S.  
corporation)  
PI US 5688767 19971118  
AI US 1996-614516 19960313 (8)  
RLI Division of Ser. No. US 1995-405234, filed on 13 Mar 1995 which is a  
continuation-in-part of Ser. No. US 1993-110502, filed on 20 Aug 1993,  
now abandoned which is a continuation-in-part of Ser. No. US  
1992-933492, filed on 21 Aug 1992, now abandoned  
DT Utility  
EXNAM Primary Examiner: Patterson, Jr, Charles L.  
LREP Fish & Richardson, P.C.  
CLMN Number of Claims: 6  
ECL Exemplary Claim: 1  
DRWN 26 Drawing Figure(s); 19 Drawing Page(s)  
LN.CNT 1709  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB A method for the microbial production of a cationic peptide having  
anti-microbial activity is provided, wherein the cationic peptide is  
first produced as a fusion protein having an anionic portion for  
suppressing the antimicrobial activity of the cationic portion. A novel  
cationic **peptide** having anti-microbial activity and  
LPS-binding activity is also provided. Such peptides are useful  
for suppressing the growth of bacteria and for the treatment of  
endotoxemia-associated disorders.

L8 ANSWER 28 OF 46 USPATFULL  
AN 97:66218 USPATFULL  
TI Biologically active peptides from functional domains of  
bactericidal/permeability-increasing protein and uses thereof  
IN Little, II, Roger G., Benicia, CA, United States  
PA XOMA, Berkeley, CA, United States (U.S. corporation)  
PI US 5652332 19970729  
AI US 1994-306473 19940915 (8)  
RLI Continuation-in-part of Ser. No. US 1994-209762, filed on 11 Mar 1994  
which is a continuation-in-part of Ser. No. US 1994-183222, filed on 14



Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93202, filed on 15 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-30644, filed on 12 Mar 1993, now patented, Pat. No. US 5348942

DT Utility

EXNAM Primary Examiner: Schain, Howard E.; Assistant Examiner: Davenport, A. M.

LREP Banner & Allegretti, Ltd.

CLMN Number of Claims: 4

ECL Exemplary Claim: 1

DRWN 94 Drawing Figure(s); 78 Drawing Page(s)

LN.CNT 4247

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and

variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.

L8 ANSWER 29 OF 46 USPATFULL

AN 97:63993 USPATFULL

TI Method and composition for the treatment of septic shock

IN Pereira, Heloise Anne, Oklahoma City, OK, United States  
Brackett, Daniel J., Seminole, OK, United States  
Lerner, Megan R., Shawnee, OK, United States

PA The Board of Regents of the University of Oklahoma, Norman, OK, United States (U.S. corporation)

PI US 5650392 19970722

AI US 1995-455485 19950531 (8)

RLI Division of Ser. No. US 1994-235399, filed on 29 Apr 1994, now patented,

Pat. No. US 5607916 which is a continuation-in-part of Ser. No. US 1992-969931, filed on 30 Oct 1992, now patented, Pat. No. US 5458874 which is a continuation of Ser. No. US 1992-855417, filed on 19 Mar 1992, now patented, Pat. No. US 5484855 which is a continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which

is

a continuation-in-part of Ser. No. US 1989-375739, filed on 5 Jul 1989, now abandoned

DT Utility

EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Harle, Jennifer

LREP Dunlap & Coddington, P.C.

CLMN Number of Claims: 3

ECL Exemplary Claim: 1

DRWN 11 Drawing Figure(s); 11 Drawing Page(s)

LN.CNT 608

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention contemplates a composition and method for treating

septic shock in a mammal or as a prophylactic treatment prior to a surgical procedure, comprising administering a therapeutically effective

amount of a bacterial lipopolysaccharide binding peptide derived from CAP37 protein. In a preferred version, the composition and method of use

may comprise a peptide comprising amino acids 20-44 of CAP37 or a subunit thereof.

L8 ANSWER 30 OF 46 USPATFULL

AN 97:38605 USPATFULL

TI Method and composition for the treatment of septic shock  
 IN Pereira, Heloise A., Edmond, OK, United States  
 PA The Board of Regents of the University of Oklahoma, Norman, OK, United States (U.S. corporation)  
 PI US 5627262 19970506  
 AI US 1995-482328 19950607 (8)  
 RLI Continuation-in-part of Ser. No. US 1994-235399, filed on 29 Apr 1994, now patented, Pat. No. US 5607916, issued on 4 Mar 1997 which is a continuation-in-part of Ser. No. US 1992-969931, filed on 30 Oct 1992, now patented, Pat. No. US 5458874, issued on 17 Oct 1995 which is a continuation of Ser. No. US 1992-855417, filed on 19 Mar 1992, now patented, Pat. No. US 5484885, issued on 16 Jan 1996 which is a continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-375739, filed on 5 Jul 1989, now abandoned  
 DT Utility  
 EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Moore, William W.  
 LREP Dunlap & Coddington, P.C.  
 CLMN Number of Claims: 11  
 ECL Exemplary Claim: 1  
 DRWN 19 Drawing Figure(s); 19 Drawing Page(s)  
 LN.CNT 839  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The present invention contemplates a composition and method for treating septic shock in a mammal or as a prophylactic treatment prior to a surgical procedure, comprising administering a therapeutically effective amount of a bacterial lipopolysaccharide binding peptide derived from CAP37 protein. In a preferred version, the composition and method of use may comprise a peptide comprising amino acids 20-44 or 120-146 of CAP37 or subunits thereof.

L8 ANSWER 31 OF 46 USPATFULL  
 AN 97:29335 USPATFULL  
 TI Methods and compositions for detecting lipopolysaccharides using CAP18 fragments  
 IN Larrick, James W., Woodside, CA, United States  
 Wright, Susan C., Saratoga, CA, United States  
 PA Panorama Research, Inc., Mountain View, CA, United States (U.S. corporation)  
 PI US 5618675 19970408  
 AI US 1994-313681 19940927 (8)  
 RLI Continuation-in-part of Ser. No. US 1992-916961, filed on 16 Jul 1992, now patented, Pat. No. US 5277707 And Ser. No. US 1992-916765, filed on 17 Jul 1992, now abandoned  
 DT Utility  
 EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Portner, Ginny Allen  
 LREP Townsend & Townsend & Crew LLP  
 CLMN Number of Claims: 5  
 ECL Exemplary Claim: 1  
 DRWN 35 Drawing Figure(s); 23 Drawing Page(s)  
 LN.CNT 1963  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Compositions and methods for the treatment and diagnosis of lipopolysaccharide-related conditions and coagulant-related disease are provided. Compositions include polypeptides which are identical or homologous to a certain cationic protein (CAP18) obtained from mammalian granulocytes, particularly including a reactive nitrogen inhibiting peptide (RNIP) fragment found at the carboxyl-terminus of CAP18. Polypeptides are capable of binding to LPS and inhibiting LPS-mediated activation of macrophage, as well as interfering with the clotting

cascade to inhibit coagulation in conditions such as disseminated intravascular coagulation. Compositions comprising the polypeptides in

a

suitable pharmaceutical carrier are also provided.

L8 ANSWER 32 OF 46 USPATFULL  
AN 97:18141 USPATFULL  
TI Method and composition for the treatment of septic shock  
IN Pereira, Heloise A., Oklahoma City, OK, United States  
Brackett, Daniel J., Seminole, OK, United States  
Lerner, Megan R., Shawnee, OK, United States  
PA The Board of Regents of the University of Oklahoma, Norman, OK, United States (U.S. corporation)  
PI US 5607916 19970304  
AI US 1994-235399 19940429 (8)  
RLI Continuation-in-part of Ser. No. US 1992-969931, filed on 30 Oct 1992, now patented, Pat. No. US 5458874, issued on 17 Oct 1995 which is a continuation of Ser. No. US 1992-855417, filed on 19 Mar 1992, now patented, Pat. No. US 5484885, issued on 16 Jan 1996 which is a continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-375739, filed on 5 Jul 1989, now abandoned  
DT Utility  
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Moore, William W.  
LREP Dunlap & Coddington, P.C.  
CLMN Number of Claims: 6  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Figure(s); 11 Drawing Page(s)  
LN.CNT 643  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention contemplates a composition and method for treating  
septic shock in a mammal or as a prophylactic treatment prior to a surgical procedure, comprising administering a therapeutically effective  
amount of a bacterial lipopolysaccharide binding peptide derived from CAP37 protein. In a preferred version, the composition and method of use  
may comprise a peptide comprising amino acids 20-44 of CAP37 or a subunit thereof.

L8 ANSWER 33 OF 46 USPATFULL  
AN 96:120869 USPATFULL  
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock  
IN Porro, Massimo, Siena, Italy  
PA Biosynth s.r.l., Siena, Italy (non-U.S. corporation)  
PI US 5589459 19961231  
AI US 1994-280397 19940726 (8)  
RLI Division of Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented,  
Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned  
DT Utility  
EXNAM Primary Examiner: Davenport, Avis M.  
LREP Hedman, Gibson & Costigan, P.C.  
CLMN Number of Claims: 14  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)  
LN.CNT 899  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention provides methods of using peptides of the formula R.sub.1 --(A--B--C).sub.n --R, wherein R.sub.1 and R are independently H  
or an amino acid residue or a fatty acid residue; A is an amino acid

residue selected from the group consisting of Lys and Arg; B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used for the removal of endotoxin from blood or sera; the detoxification of bacterial endotoxin; and the prevention of the contamination of products with endotoxin.

L8 ANSWER 34 OF 46 USPATFULL  
AN 96:82450 USPATFULL  
TI Methods and vaccines comprising surface-active copolymers  
IN Hunter, Robert L., Tucker, GA, United States  
PA Emory University, Atlanta, GA, United States (U.S. corporation)  
PI US 5554372 19960910  
AI US 1995-420333 19950411 (8)  
RLI Continuation of Ser. No. US 1993-133760, filed on 7 Oct 1993, now abandoned which is a continuation of Ser. No. US 1991-716807, filed on 21 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-544831, filed on 27 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-449086, filed on 8 Dec 1989, now abandoned which is a continuation of Ser. No. US 1989-341315, filed on 21 Apr 1989, now abandoned which is a continuation of Ser. No. US 1988-208335, filed on 17 Jun 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-75187, filed on 16 Jul 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-909964, filed on 22 Sep 1986, now abandoned  
DT Utility  
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Shaver, Jennifer  
LREP Jones & Askew  
CLMN Number of Claims: 8  
ECL Exemplary Claim: 1  
DRWN 24 Drawing Figure(s); 17 Drawing Page(s)  
LN.CNT 2669

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention comprises adjuvants which, when admixed with an antigen and administered into a human or animal, will induce a more intense immune response to the antigen than when the antigen is administered alone. In many cases, the adjuvant that is described as the

present invention will increase overall titer of antibodies of a specific isotype which are specific for the antigen. For example, in mice, when the adjuvant of the present invention is admixed with a conventional antigen, the isotype that is induced in the mouse is changed from a predominantly IgG1 isotype to the more protective IgG2 isotype and, in some cases, IgG3 isotype. Thus, by practicing the present invention, one can improve the overall protective effect of conventional vaccines.

L8 ANSWER 35 OF 46 USPATFULL  
AN 96:34020 USPATFULL  
TI Method for using polymyxin-coated substrate for lipopolysaccharide detection  
IN Blais, Burton W., 78 Welsh Private Road, Ottawa, Ontario, Canada K1G 4Y1  
Yamazaki, Hiroshi, 22 Alderbrook Drive, Nepean, Ontario, Canada K2H 5W5  
PI US 5510242 19960423  
AI US 1993-87013 19930707 (8)  
RLI Continuation of Ser. No. US 1991-697683, filed on 9 May 1991, now abandoned  
PRAI CA 1990-2017093 19900518  
CA 1991-2037726 19910307  
CA 1991-2037727 19910307  
DT Utility

EXNAM Primary Examiner: Walsh, Stephen G.; Assistant Examiner: Kemmerer, Elizabeth C.

LREP Nixon & Vanderhye

CLMN Number of Claims: 12

ECL Exemplary Claim: 1

DRWN 7 Drawing Figure(s); 3 Drawing Page(s)

LN.CNT 1768

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An improved device is provided which may be used, e.g. for immunoassay of lipopolysaccharides or for removing LPS pyrogens from aqueous solutions, or for removing LPS endotoxins from wounds. Such device comprises, in combination, a substrate, e.g. plastic, i.e. polystyrene, polycarbonate, polymethylmethacrylate or polyvinyl chloride, or a woven cloth, i.e. a rayon/polyester cloth or a polyester cloth, or a

non-woven

cloth, i.e. a rayon/polyester cloth, or a polyester cloth, or paper, which is adapted to receive a sample to be tested, and an oligopeptide, or a hydrophobic polypeptide or a polymyxin, e.g. polymyxin B,

polymyxin

B.sub.1, polymyxin B.sub.2, polymyxin D.sub.1, polymyxin D.sub.2, or polymyxin E, adhered to the substrate.

L8 ANSWER 36 OF 46 USPATFULL

AN 96:29533 USPATFULL

TI Muramyl compounds for treatment of septic shock

IN Aston, Roger, Malmesbury, United Kingdom

PA Peptech (UK) Limited, England (non-U.S. corporation)

PI US 5506204 19960409

WO 9310148 19930527

AI US 1994-244154 19940518 (8)

WO 1992-GB2137 19921119

19940518 PCT 371 date

19940518 PCT 102(e) date

PRAI GB 1991-24500 19911119

GB 1992-10013 19920508

DT Utility

EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: Prickril, Benet

LREP Banner & Allegretti, Ltd.

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN 8 Drawing Figure(s); 4 Drawing Page(s)

LN.CNT 931

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Muramyl peptide compounds which: (a) are non-pyrogenic; and/or (b) ameliorate endotoxin-induced weight loss and/or hypophagia; and/or (c) reduce TNF production; and/or (d) stimulate macrophage to produce endotoxin are useful, in the treatment of septic shock, cachexia and other life-threatening inflammatory conditions. Preferred compounds include N-acetyl-glucosaminyl-N-acetyl-muramyl-L-alanyl-D-isoglutamine (GMDP) and N-acetyl-glucosaminyl-N-acetyl-muramyl-L-alanyl-D-glutamic acid (GMDP-A).

L8 ANSWER 37 OF 46 USPATFULL

AN 96:5884 USPATFULL

TI Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments

of CAP37

IN Pereira, Heloise A., Decatur, GA, United States

Spitznagel, John K., Decatur, GA, United States

PA Emory University, Atlanta, GA, United States (U.S. corporation)

PI US 5484885 19960116

AI US 1992-855417 19920319 (7)

RLI Continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US

1989-375739, filed on 5 Jul 1989, now abandoned

DT Utility

EXNAM Primary Examiner: Furman, Keith C.

LREP Needle & Rosenberg

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN 20 Drawing Figure(s); 20 Drawing Page(s)

LN.CNT 2498

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a homogeneously pure monocyte chemotactic protein, CAP37, and the entire coding sequences for unprocessed and mature human CAP37 protein. Further, the recombinant production, from nucleic acid coding sequences, of mature CAP37 protein and the mature protein with amino-terminal and/or carboxy-terminal extensions is described. Also disclosed are methods to identify and recombinantly produce bioactive peptides derived from the CAP37 protein coding sequence which are effective chemoattractants of monocytes and/or are capable of binding bacterial lipopolysaccharide. A method of preparing homogeneously pure CAP37 using hydrophobic HPLC is described. Bioactive peptide fragments of CAP37 having chemotactic, antibacterial and/or LPS-binding activity are disclosed. Finally, methods of treating wounds, diseased tissue, such as tumors, and infections are described.

L8 ANSWER 38 OF 46 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD  
DUPLICATE

2

AN 1995-098719 [13] WPIDS

DNN N1995-077922 DNC C1995-044944

TI New lipo polysaccharide binding and neutralising peptide(s) - used for treating or preventing LPS associated conditions or for detecting or removing bacterial LPS..

DC B04 C03 D16 S03

IN HOESS, A; LIDDINGTON, R C

PA (MORP-N) MORPHOSYS AG; (MORP-N) MORPHOSYS GES PROTEINOPTIMIERUNG MBH

CYC 20

PI WO 9505393 A2 19950223 (199513)\* EN 45p  
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE  
W: CA JP US  
EP 664814 A1 19950802 (199535) EN  
R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE  
WO 9505393 A3 19950323 (199613)  
JP 08503490 W 19960416 (199645) 56p

ADT WO 9505393 A2 WO 1994-EP2747 19940818; EP 664814 A1 EP 1994-926848 19940818, WO 1994-EP2747 19940818; WO 9505393 A3 WO 1994-EP2747 19940818; JP 08503490 W WO 1994-EP2747 19940818, JP 1995-506764 19940818

FDT EP 664814 A1 Based on WO 9505393; JP 08503490 W Based on WO 9505393

PRAI US 1993-111625 19930825; US 1993-108415 19930818

AB WO 9505393 A UPAB: 19990424  
(A) A lipopolysaccharide (LPS) - binding peptide is claimed comprising a LPS binding domain comprising at least (a) the amino acid sequence A1-A2-A3-A4-A5-A6-A7-A8 (I), in which A1 = a polar or positively charged amino acid, pref. C, H, K, N, Q, R, S, T, W or Y; A2 = a hydrophobic amino acid, pref. A, F, H, I, L, M, V or W; A3 = a basic amino acid, pref. H, K or R; A4 = a hydrophobic or positively charged amino acid, pref. A, F, H, I, K, L, M, R, V or W; A5 = a hydrophobic, polar or positively charged amino acid, pref. A, C, F, H, I, K, L, M, N, Q, R, S, T, V, W or Y; A6 = a positively charged amino acid, pref. K or R; A7 = as for A5; A8 = as for A4; (b) a corresp. inverse amino acid sequence; or (c) a variation of the amino acid sequence (a) or (b) capable of effectively binding to LPS. Also claimed are: (B) a DNA sequence encoding a peptide as in (A); (C) a recombinant vector contg. a DNA

sequence as in (B); (D) a microorganism contg. a recombinant vector as in (C) (E) a diagnostic kit contg. an **LPS-binding peptide** as in (A) or a set of such peptides.

USE - The peptides can be used for treating Gram-negative or Gram-positive sepsis, **bacterial** or fungal **infections** or heparin-mediated anti-coagulation (claimed). They can also be used for inhibition of angiogenesis, tumour cell proliferation or endothelial cell proliferation (claimed). They can also be used for diagnosis, e.g. of septic conditions (claimed). They can also be immobilised and used for removing LPS or bacteria from solns. (claimed).

ADVANTAGE - The peptides effectively bind to LPS and interact specifically with LPS with an association constant  $> 10^5 \text{ M}^{-1}$ . The peptides

also show bactericidal and heparin binding activity.  
Dwg.0/15

L8 ANSWER 39 OF 46 USPATFULL  
AN 95:92525 USPATFULL  
TI Method of increasing monocyte chemotaxis with CAP37 and monocyte chemotactic portions thereof  
IN Pereira, Heloise A., Decatur, GA, United States  
Spitznagel, John K., Decatur, GA, United States  
PA Emory University, Atlanta, GA, United States (U.S. corporation)  
PI US 5458874 19951017  
AI US 1992-969931 19921030 (7)  
RLI Continuation of Ser. No. US 1992-855417, filed on 18 Mar 1992 which is a continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-375739, filed on 5 Jul 1989, now abandoned  
DT Utility  
EXNAM Primary Examiner: Furman, Keith C.  
LREP Needle & Rosenberg  
CLMN Number of Claims: 4  
ECL Exemplary Claim: 1  
DRWN 20 Drawing Figure(s); 20 Drawing Page(s)  
LN.CNT 2618  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Disclosed is a homogeneously pure monocyte chemotactic protein, CAP37, and the entire coding sequences for unprocessed and mature human CAP37 protein. Further, the recombinant production, from nucleic acid coding sequences, of mature CAP37 protein and the mature protein with amino-terminal and/or carboxy-terminal extensions is described. Also disclosed are methods to identify and recombinantly produce bioactive peptides derived from the CAP37 protein coding sequence which are effective chemoattractants monocytes and/or are capable of binding bacterial lipopolysaccharide. A method of preparing homogeneously pure CAP37 using hydrophobic HPLC is described. Bioactive peptide fragments of CAP37 having chemotactic, antibacterial and/or LPS-binding activity are disclosed. Finally, methods of treating wounds, diseased tissue, such as tumors, and infections are described.

L8 ANSWER 40 OF 46 USPATFULL  
AN 94:106884 USPATFULL  
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock  
IN Porro, Massimo, Siena, Italy  
PA Biosynth S.r.l., Siena, Italy (non-U.S. corporation)  
PI US 5371186 19941206  
AI US 1992-819893 19920116 (7)  
DCD 20111025  
RLI Continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned  
DT Utility  
EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Davenport, A. M.

LREP Hedman, Gibson & Costigan  
CLMN Number of Claims: 11  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)  
LN.CNT 852

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel peptides of the formula  $R_{sub.1}-(A-B-C)_{sub.n}-R$ , where  $R_{sub.1}$  and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys, Arg, and His; B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used inter alia for the

prevention

and/or treatment of septic shock, for the detection of endotoxin and the

preparation of antigenic complexes of Lipid A.

L8 ANSWER 41 OF 46 USPATFULL

AN 94:93312 USPATFULL

TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock

IN Porro, Massimo, Siena, Italy

PA BiosYnth S.r.l., Siena, Italy (non-U.S. corporation)

PI US 5358933 19941025

AI US 1993-49871 19930419 (8)

RLI Continuation of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned

DT Utility

EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Marshall, S. G.

LREP Hedman, Gibson & Costigan

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 483

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel peptides are disclosed which are based on the formula:

$R_{sub.1}-(Lys-Phe-Leu)_{sub.n}-R$

amino wherein n is an integer of from 1-10 and R and  $R_{sub.1}$  are H or an

acid residue or a fatty acid residue which are useful in the treatment of septic shock.

L8 ANSWER 42 OF 46 USPATFULL

AN 93:14545 USPATFULL

TI Method of treating cellular Fc receptor mediated hypersensitivity immune disorders

IN Cowan, Jr., Fred M., 21 Shady Brook Dr., Colora, MD, United States 21917

PI US 5189014 19930223

AI US 1991-711709 19910607 (7)

RLI Continuation of Ser. No. US 1989-424088, filed on 19 Oct 1989, now abandoned which is a continuation-in-part of Ser. No. US 1986-911341, filed on 25 Sep 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-728142, filed on 26 Apr 1985, now abandoned which is a continuation of Ser. No. US 1980-204945, filed on 7 Nov 1980, now abandoned which is a continuation-in-part of Ser. No. US 1979-99741, filed on 3 Dec 1979, now abandoned

DT Utility

EXNAM Primary Examiner: Waddell, Frederick E.; Assistant Examiner: Hook, Gregory

LREP Field, Milton M.



CLMN Number of Claims: 13  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1756

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of immunotherapy for treating diseases and disorders which involve cellular Fc receptor mediated immune responses in humans and animals is disclosed. Abnormal or undesirable cellular Fc receptor mediated immune reactions are beneficially altered by locally or systemically administering an exogenous Fc receptor polypeptide, in particular a multivalent protein having in its molecule several Fc receptor sites, such as staphylococcus protein A, or monovalent Fc receptor possessing only a single Fc receptor site.

L8 ANSWER 43 OF 46 CAPLUS COPYRIGHT 2000 ACS

AN 1993:574194 CAPLUS

DN 119:174194

TI Muramyl peptide compounds for treatment of septic shock

IN Aston, Roger

PA Biokine Technology Ltd., UK

SO PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9310148	A1	19930527	WO 1992-GB2137	19921119
	W: AU, BG, BR, CA, CS, FI, HU, JP, KR, NO, PL, RO, RU, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
	AU 9229492	A1	19930615	AU 1992-29492	19921119
	AU 666890	B2	19960229		
	ZA 9208958	A	19940519	ZA 1992-8958	19921119
	EP 615522	A1	19940921	EP 1992-923873	19921119
	EP 615522	B1	19990922		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
	JP 07508497	T2	19950921	JP 1992-509106	19921119
	RU 2139086	C1	19991010	RU 1994-27574	19921119
	AT 184883	E	19991015	AT 1992-923873	19921119
	US 5506204	A	19960409	US 1994-244154	19940518
PRAI	GB 1991-24500		19911119		
	GB 1992-10013		19920508		
	WO 1992-GB2137		19921119		

OS MARPAT 119:174194

AB Muramyl peptide compds. which (1) are nonpyrogenic; and/or (2) ameliorate endotoxin-induced wt. loss and/or hypophagia; and/or (3) reduce TNF prodn.; and/or (4) stimulate macrophages to process endotoxin are useful in the treatment of septic shock, cachexia, and other life-threatening inflammatory conditions. Preferred compds. include

N-acetyl-glucosaminy-

N-acetyl-muramyl-L-alanyl-D-isoglutamine (I) and N-acetyl-glucosaminy-N-acetyl-muramyl-L-alanyl-D-glutamic acid. Thus, in patients undergoing surgery for colon cancer, treatment with I reduced the incidence of

septic

complications from 50 to 18.75%. Importantly and more specifically, the redn. in mortality from 15 to 6.25% gives an indication of the effectiveness of the invention in treating or preventing septic shock, which is frequently the cause of death in such mortalities. Neutrophil function was maintained in the I-treated patients.

L8 ANSWER 44 OF 46 USPATFULL

AN 92:12734 USPATFULL

TI Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders

IN Marra, Marian N., San Mateo, CA, United States

Scott, Randal W., Sunnyvale, CA, United States  
 PA INCYTE Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)  
 PI US 5089274 19920218  
 AI US 1990-468696 19900122 (7)  
 RLI Continuation-in-part of Ser. No. US 1989-310842, filed on 14 Feb 1989, now abandoned  
 DT Utility  
 EXNAM Primary Examiner: Robinson, Douglas W.; Assistant Examiner: Witz, Jean C.  
 LREP White, John P.  
 CLMN Number of Claims: 25  
 ECL Exemplary Claim: 4  
 DRWN 20 Drawing Figure(s); 20 Drawing Page(s)  
 LN.CNT 1117  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The present invention provides a method of inhibiting lipopolysaccharide (LPS)-mediated stimulation of cells. This method comprises contacting the cells, in the presence of a cell-stimulating amount of lipopolysaccharide, with Bactericidal/Permeability Increasing Protein (BPI) in an amount effective to inhibit cell stimulation.

L8 ANSWER 45 OF 46 BIOSIS COPYRIGHT 2000 BIOSIS  
 AN 1990:109561 BIOSIS  
 DN BA89:59052  
 TI LIPOPOLYSACCHARIDE MODULATES CHEMOTACTIC PEPTIDE-INDUCED ACTIN POLYMERIZATION IN NEUTROPHILS.  
 AU HOWARD T H; WANG D; BERKOW R L  
 CS DEP. PEDIATR., DIV. HEMATOL.-ONCOL., CHILD. HOSP. ALA., 1600 7TH AVE. SOUTH, BIRMINGHAM, ALA. 35223.  
 SO J LEUKOCYTE BIOL, (1990) 47 (1), 13-24.  
 CODEN: JLBIE7. ISSN: 0741-5400.  
 FS BA; OLD  
 LA English  
 AB To study the effect of endotoxin (LPS) on the basal and chemotactic peptide, formyl-methionyl-leucyl-phenylalanine (fMLP)-induced alterations in neutrophil cytoskeleton, we purified (> 98%) LPS-free neutrophils (LPS- < 10 pg/ml LPS), compared their cytoskeletal organization to that of circulating neutrophils, and examined the effect of LPS exposure on the basal and fMLP-induced change in the cytoskeleton as reflected by F-actin content and distribution. Shape, F-actin content and distribution were monitored by FACS analysis and fluorescence microscopy of NBDphalloidin-stained cells. The F-actin content of basal and fMLP-activated, purified LPS- cells is similar to that of circulating neutrophils (defined as cells drawn in LPS- buffers at 37.degree. C and analyzed after < 10 seconds of ex vivo manipulation). LPS- cells are round with a diffuse F-actin distribution. Exposure of LPS- cells to LPS causes cell polarization and F-actin redistribution without net gain in F-actin content. Peptide activation of the LPS- cell causes actin polymerization, which is preceded by a brief lag time. Exposure of LPS- cells to LPS (LPS+) enhances fMLP-induced actin polymerization by:

- 1) increasing the maximal extent of polymerization; 2) shortening the lag time preceding polymerization and increasing the rate of polymerization; and 3) lowering fMLP dose required for half maximal F-actin response. The enhancement depends on LPS dose, duration of exposure, and temperature.

To examine the mechanism whereby LPS enhances fMLP-induced actin polymerization, we determined the predominant end for filament growth in LPS- and LPS+ cells, the number of actin nuclei generated in LPS- and LPS+ by fMLP activation, and the number and affinity of fMLP receptors on LPS-

and LPS+ cells by 3[H]fMLP binding. Actin polymerization in both LPS- and LPS+ occurs predominantly by monomer addition to the barbed ends of nuclei, and the number of actin nuclei in basal and fMLP-activated LPS- and LPS+ cells is similar. LPS+ cells express three times more fMLP receptors than LPS- cells. The results show that LPS- cells are similar in cytoskeletal organization to circulating neutrophils, LPS causes shape change without change in F-actin content, and LPS enhances fMLP-induced actin polymerization response in neutrophils. The results suggest that LPS enhancement of actin polymerization response is associated with an increase in the number of fMLP receptors expressed on the cell surface.

L8 ANSWER 46 OF 46 MEDLINE  
 AN 88214962 MEDLINE  
 DN 88214962  
 TI Immunosuppressive effects of a trauma-induced suppressor active peptide.  
 AU Ozkan A N; Hoyt D B; Tompkins S; Ninnemann J L; Sullivan J J  
 CS Department of Surgery, University of California San Diego, School of Medicine.  
 NC GM-34007 (NIGMS)  
 SO JOURNAL OF TRAUMA, (1988 May) 28 (5) 589-92.  
 Journal code: KAF. ISSN: 0022-5282.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 198808  
 AB The isolation and partial characterization of an immunosuppressive glycopeptide from sera of severely burned patients has previously been reported. Recently, a monoclonal antibody to this factor and an enzyme linked immunosorbent assay for detection of the peptide have been developed. The presence of the peptide in elevated quantity has been demonstrated in serum of patients with multiple blunt trauma as well as thermally injured patients. It was determined that the peptide is capable of suppressing neutrophil chemotaxis and T-cell blastogenesis as measured by MLR. Inhibition of B-cell blastogenesis induced by the peptide as measured by LPS mitogen-induced proliferation was demonstrated to be less sensitive to suppression. Further, it appears that activated T lymphocytes, those expressing increased IL-2 receptors, are more sensitive to suppression by the peptide at lower concentrations than are nonactivated T lymphocytes.

=> d his

(FILE 'HOME' ENTERED AT 11:34:20 ON 30 OCT 2000)

FILE 'EMBASE, MEDLINE, BIOSIS, USPATFULL, JAPIO, WPIDS, CAPLUS, BIOTECHDS, AGRICOLA' ENTERED AT 11:35:33 ON 30 OCT 2000  
 E PORRO MASSIMO/AU

L1 39 S E3  
 L2 8 S L1 AND SEPSIS  
 L3 7 DUP REM L2 (1 DUPLICATE REMOVED)  
 L4 7 S L1 AND LPS (5A) PEPTIDE  
 L5 1 S L1 AND GRAM NEGATIVE BACTERIAL INFECT?  
 L6 157699 S BACTERIAL (5A) INFECT?  
 L7 50 S L6 AND LPS (5A) PEPTIDE  
 L8 46 DUP REM L7 (4 DUPLICATES REMOVED)

=> s l6 and lps (10a) synthetic peptid?

L9 8 L6 AND LPS (10A) SYNTHETIC PEPTID?

=> dup rem 19

PROCESSING COMPLETED FOR L9

L10 8 DUP REM L9 (0 DUPLICATES REMOVED)

=> d bib ab 1-8

L10 ANSWER 1 OF 8 USPATFULL

AN 96:120869 USPATFULL

TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock

IN Porro, Massimo, Siena, Italy

PA BiosYnth s.r.l., Siena, Italy (non-U.S. corporation)

PI US 5589459 19961231

AI US 1994-280397 19940726 (8)

RLI Division of Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented,

Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned

DT Utility

EXNAM Primary Examiner: Davenport, Avis M.

LREP Hedman, Gibson & Costigan, P.C.

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 899

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods of using peptides of the formula R.sub.1 --(A--B--C).sub.n --R, wherein R.sub.1 and R are independently

H

or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys and Arg; B is an

amino

acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used for the removal of endotoxin from blood or sera; the detoxification of bacterial endotoxin; and the prevention of the contamination of products with endotoxin.

L10 ANSWER 2 OF 8 USPATFULL

AN 96:5884 USPATFULL

TI Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37

IN Pereira, Heloise A., Decatur, GA, United States

Spitznagel, John K., Decatur, GA, United States

PA Emory University, Atlanta, GA, United States (U.S. corporation)

PI US 5484885 19960116

AI US 1992-855417 19920319 (7)

RLI Continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-375739, filed on 5 Jul 1989, now abandoned

DT Utility

EXNAM Primary Examiner: Furman, Keith C.

LREP Needle & Rosenberg

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN 20 Drawing Figure(s); 20 Drawing Page(s)

LN.CNT 2498

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a homogeneously pure monocyte chemotactic protein, CAP37, and the entire coding sequences for unprocessed and mature human CAP37 protein. Further, the recombinant production, from nucleic acid coding

sequences, of mature CAP37 protein and the mature protein with amino-terminal and/or carboxy-terminal extensions is described. Also disclosed are methods to identify and recombinantly produce bioactive peptides derived from the CAP37 protein coding sequence which are effective chemoattractants of monocytes and/or are capable of binding bacterial lipopolysaccharide. A method of preparing homogeneously pure CAP37 using hydrophobic HPLC is described. Bioactive peptide fragments of CAP37 having chemotactic, antibacterial and/or LPS-binding activity are disclosed. Finally, methods of treating wounds, diseased tissue, such as tumors, and infections are described.

L10 ANSWER 3 OF 8 USPATFULL

AN 95:92525 USPATFULL

TI Method of increasing monocyte chemotaxis with CAP37 and monocyte chemotactic portions thereof

IN Pereira, Heloise A., Decatur, GA, United States

Spitznagel, John K., Decatur, GA, United States

PA Emory University, Atlanta, GA, United States (U.S. corporation)

PI US 5458874 19951017

AI US 1992-969931 19921030 (7)

RLI Continuation of Ser. No. US 1992-855417, filed on 18 Mar 1992 which is a

continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-375739, filed on 5 Jul 1989, now abandoned

DT Utility

EXNAM Primary Examiner: Furman, Keith C.

LREP Needle & Rosenberg

CLMN Number of Claims: 4

ECL Exemplary Claim: 1

DRWN 20 Drawing Figure(s); 20 Drawing Page(s)

LN.CNT 2618

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a homogeneously pure monocyte chemotactic protein, CAP37, and the entire coding sequences for unprocessed and mature human CAP37 protein. Further, the recombinant production, from nucleic acid coding sequences, of mature CAP37 protein and the mature protein with amino-terminal and/or carboxy-terminal extensions is described. Also disclosed are methods to identify and recombinantly produce bioactive peptides derived from the CAP37 protein coding sequence which are effective chemoattractants monocytes and/or are capable of binding bacterial lipopolysaccharide. A method of preparing homogeneously pure CAP37 using hydrophobic HPLC is described. Bioactive peptide fragments of CAP37 having chemotactic, antibacterial and/or LPS-binding activity are disclosed. Finally, methods of treating wounds, diseased tissue, such as tumors, and infections are described.

L10 ANSWER 4 OF 8 USPATFULL

AN 95:45359 USPATFULL

TI Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres

IN Reid, Robert H., Kensington, MD, United States

Boedeker, Edgar C., Chevy Chase, MD, United States

van Hamont, John E., Shape, Belgium

Setterstrom, Jean A., Takoma Park, MD, United States

PA The United States of America as represented by the Secretary of the Army, Washington, DC, United States (U.S. government)

PI US 5417986 19950523

AI US 1992-867301 19920410 (7)

RLI Continuation-in-part of Ser. No. US 1991-805721, filed on 21 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-690485, filed on 24 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-521945, filed on 11 May 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-493597, filed on 15 Mar 1990, now abandoned which is a

continuation-in-part of Ser. No. US 1984-590308, filed on 16 Mar 1984  
DT Utility  
EXNAM Primary Examiner: Henley, III, Raymond J.; Assistant Examiner: Criares, T. J.  
LREP Lane, Anthony T.; Reichert, Earl T.; Bellamy, Werten F. W.  
CLMN Number of Claims: 14  
ECL Exemplary Claim: 1  
DRWN 71 Drawing Figure(s); 70 Drawing Page(s)  
LN.CNT 2736  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB This invention is directed to oral parenteral and intestinal vaccines and eir use against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres.

L10 ANSWER 5 OF 8 USPATFULL

AN 94:106884 USPATFULL

TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock

IN Porro, Massimo, Siena, Italy

PA Biosynth S.r.l., Siena, Italy (non-U.S. corporation)

PI US 5371186 19941206

AI US 1992-819893 19920116 (7)

DCD 20111025

RLI Continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned

DT Utility

EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Davenport, A. M.

LREP Hedman, Gibson & Costigan

CLMN Number of Claims: 11

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 852

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel peptides of the formula R.sub.1 - (A-B-C).sub.n -R, where R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys, Arg, and His; B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used inter alia for the

prevention

and/or treatment of septic shock, for the detection of endotoxin and

the

preparation of antigenic complexes of Lipid A.

L10 ANSWER 6 OF 8 USPATFULL

AN 94:93312 USPATFULL

TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock

IN Porro, Massimo, Siena, Italy

PA Biosynth S.r.l., Siena, Italy (non-U.S. corporation)

PI US 5358933 19941025

AI US 1993-49871 19930419 (8)

RLI Continuation of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned

DT Utility

EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Marshall, S. G.

LREP Hedman, Gibson & Costigan

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 483

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel peptides are disclosed which are based on the formula:

R.sub.1 (Lys-Phe-Leu).sub.n --R

wherein n is an integer of from 1-10 and R and R.sub.1 are H or an amino acid residue or a fatty acid residue which are useful in the treatment of septic shock.

L10 ANSWER 7 OF 8 USPATFULL

AN 94:82236 USPATFULL

TI Therapeutic uses of bactericidal/permeability increasing protein products

IN Little, II, Roger G., Benicia, CA, United States

Gazzano-Santoro, Helene, San Bruno, CA, United States

Parent, James B., Oakland, CA, United States

PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)

PI US 5348942 19940920

AI US 1993-30644 19930312 (8)

DT Utility

EXNAM Primary Examiner: Furman, Keith C.

LREP Marshall, O'Toole, Gerstein, Murray & Borun

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN 13 Drawing Figure(s); 8 Drawing Page(s)

LN.CNT 997

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides therapeutic methods for treatment of conditions including the neutralization of the anti-coagulant activity of heparin, inhibition of angiogenesis, tumor and endothelial cell proliferation, and treatment of chronic inflammatory diseases by administration of bactericidal/permeability-increasing (BPI) protein products.

L10 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2000 ACS

AN 1994:94826 CAPLUS

DN 120:94826

TI Unique endotoxin-neutralizing proteins: inhibition of endotoxin-induced tissue factor generation

AU Hirata, Michimasa; Shimomura, Yuko; Yoshida, Masao

CS Sch. Med., Iwate Med. Univ., Morioka, 020, Japan

SO Nippon Kessen Shiketsu Gakkaishi (1993), 4(3), 153-62

CODEN: NKSSEL; ISSN: 0915-7441

DT Journal

LA Japanese

AB Cationic antibacterial proteins (CAP), intracellular lipopolysaccharide (LPS)-binding proteins, were isolated from rabbit peritoneal granulocytes using an assay of the agglutination of erythrocytes coated with Re-LPS. Mol. wt. of CAP estd. by SDS-PAGE was 7 kDa (CAP-7) and 18 kDa (CAP-18), and CAP-7 had high contents of cationic residues. LPS activates murine macrophages and human blood monocytes to generate tissue factor (tissue thromboplastin). After 18 h incubation of LPS prepns. with CAP (heparin-sepharose fraction), S-LPS, Re-LPS and lipid A-induced tissue factor activities were inhibited. S-LPS was inactivated more rapidly

than

Re-LPS and lipid A. Within 1 h after incubation, purified CAP-18 inhibited about 75% of the activity of S-LPS. CAP-7 also inhibited LPS-induced tissue factor generation by human blood monocytes. LPS-binding, and LPS-neutralizing activities of CAP-7 were higher than those of CAP-18. **Synthetic peptide** #197-1 (having identical structure to CAP-7) also showed **LPS-binding** and **LPS-neutralizing** activities. Disseminated intravascular coagulation

(DIC)

manifestation in endotoxemia, due to gram-neg. **bacterial infections**, are controlled by CAP released from granulocytes. In addn., CAP-7 and CAP-18 may have therapeutic potential for septic and endotoxin shock.

=> d his

(FILE 'HOME' ENTERED AT 11:34:20 ON 30 OCT 2000)

FILE 'EMBASE, MEDLINE, BIOSIS, USPATFULL, JAPIO, WPIDS, CAPLUS,  
BIOTECHDS, AGRICOLA' ENTERED AT 11:35:33 ON 30 OCT 2000  
E PORRO MASSIMO/AU

L1 39 S E3  
L2 8 S L1 AND SEPSIS  
L3 7 DUP REM L2 (1 DUPLICATE REMOVED)  
L4 7 S L1 AND LPS (5A) PEPTIDE  
L5 1 S L1 AND GRAM NEGATIVE BACTERIAL INFECT?  
L6 157699 S BACTERIAL (5A) INFECT?  
L7 50 S L6 AND LPS (5A) PEPTIDE  
L8 46 DUP REM L7 (4 DUPLICATES REMOVED)  
L9 8 S L6 AND LPS (10A) SYNTHETIC PEPTID?  
L10 8 DUP REM L9 (0 DUPLICATES REMOVED)

=> s l6 and endotox?

L11 4036 L6 AND ENDOTOX?

=> s l11 and lps

L12 1284 L11 AND LPS

=> s l12 and meningitidis

L13 0 L12 AND MENINGITIDIS

=> s l12 and sepsis

L14 476 L12 AND SEPSIS

=> dup rem l14

PROCESSING COMPLETED FOR L14

L15 421 DUP REM L14 (55 DUPLICATES REMOVED)

=> s l14 and synthetic peptid?

L16 48 L14 AND SYNTHETIC PEPTID?

=> dup rem l16

PROCESSING COMPLETED FOR L16

L17 48 DUP REM L16 (0 DUPLICATES REMOVED)

=> d his

(FILE 'HOME' ENTERED AT 11:34:20 ON 30 OCT 2000)

FILE 'EMBASE, MEDLINE, BIOSIS, USPATFULL, JAPIO, WPIDS, CAPLUS,  
BIOTECHDS, AGRICOLA' ENTERED AT 11:35:33 ON 30 OCT 2000  
E PORRO MASSIMO/AU

L1 39 S E3  
L2 8 S L1 AND SEPSIS  
L3 7 DUP REM L2 (1 DUPLICATE REMOVED)  
L4 7 S L1 AND LPS (5A) PEPTIDE  
L5 1 S L1 AND GRAM NEGATIVE BACTERIAL INFECT?  
L6 157699 S BACTERIAL (5A) INFECT?



L7 50 S L6 AND LPS (5A) PEPTIDE  
 L8 46 DUP REM L7 (4 DUPLICATES REMOVED)  
 L9 8 S L6 AND LPS (10A) SYNTHETIC PEPTID?  
 L10 8 DUP REM L9 (0 DUPLICATES REMOVED)  
 L11 4036 S L6 AND ENDOTOX?  
 L12 1284 S L11 AND LPS  
 L13 0 S L12 AND MENIGITIDIS  
 L14 476 S L12 AND SEPSIS  
 L15 421 DUP REM L14 (55 DUPLICATES REMOVED)  
 L16 48 S L14 AND SYNTHETIC PEPTID?  
 L17 48 DUP REM L16 (0 DUPLICATES REMOVED)

=> d bib 1-48

L17 ANSWER 1 OF 48 USPATFULL  
 AN 2000:109964 USPATFULL  
 TI Antimicrobial peptides and methods of use thereof  
 IN Pereira, H. Anne, Edmond, OK, United States  
 PA The Board of Regents of the University of Oklahoma, Norman, OK, United States (U.S. corporation)  
 PI US 6107460 20000822  
 AI US 1999-258934 19990301 (9)  
 DT Utility  
 EXNAM Primary Examiner: Carlson, Karen Cochrane; Assistant Examiner: Srivastava, Deven  
 LREP Dunlap, Coddling & Rogers  
 CLMN Number of Claims: 5  
 ECL Exemplary Claim: 1  
 DRWN 20 Drawing Figure(s); 20 Drawing Page(s)  
 LN.CNT 1073  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 2 OF 48 USPATFULL  
 AN 2000:106071 USPATFULL  
 TI Mammalian cationic proteins having lipopolysaccharide binding and anti-coagulant activity  
 IN Larrick, James W., Woodside, CA, United States  
 Wright, Susan C., Saratoga, CA, United States  
 Hirata, Michimasa, Morioka, Japan  
 PA Panorama Research, Inc., Mountain View, CA, United States (U.S. corporation)  
 PI US 6103888 20000815  
 AI US 1999-322911 19990601 (9)  
 RLI Continuation of Ser. No. US 1996-691280, filed on 1 Aug 1996 which is a continuation-in-part of Ser. No. US 313681  
 DT Utility  
 EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Portner, Ginny Allen  
 LREP Townsend and Townsend and Crew  
 CLMN Number of Claims: 1  
 ECL Exemplary Claim: 1  
 DRWN 30 Drawing Figure(s); 20 Drawing Page(s)  
 LN.CNT 1944  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 3 OF 48 USPATFULL  
 AN 2000:94872 USPATFULL  
 TI Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)  
 IN Beamer, Lesa J., Santa Monica, CA, United States  
 Carroll, Stephen F., Walnut Creek, CA, United States  
 Eisenberg, David, Los Angeles, CA, United States  
 PA XOMA, Berkeley, CA, United States (U.S. corporation)  
 The Regents of the University of California, Oakland, CA, United States

(U.S. corporation)  
PI US 6093573 20000725  
AI US 1997-879565 19970620 (8)  
DT Utility  
EXNAM Primary Examiner: Nashed, Nashaat  
LREP McAndrews, Held & Malloy, Ltd.  
CLMN Number of Claims: 6  
ECL Exemplary Claim: 1  
DRWN 126 Drawing Figure(s); 125 Drawing Page(s)  
LN.CNT 2940  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 4 OF 48 USPATFULL  
AN 2000:80408 USPATFULL  
TI Compositions for the prevention and treatment of verotoxin-induced  
disease  
IN Williams, James A., Lincoln, NE, United States  
Byrne, Lisa Marie, Stoughton, WI, United States  
PA Ophidian Pharmaceuticals, Inc., Wisconsin, United States (U.S.  
corporation)  
PI US 6080400 20000627  
AI US 1997-816977 19970313 (8)  
RLI Continuation-in-part of Ser. No. US 1995-410058, filed on 24 Mar 1995,  
now abandoned  
DT Utility  
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Devi, S.  
LREP Medlen & Carroll, LLP  
CLMN Number of Claims: 2  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Figure(s); 9 Drawing Page(s)  
LN.CNT 5468  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 5 OF 48 USPATFULL  
AN 2000:70809 USPATFULL  
TI Method for the treatment of **bacterial infection**  
IN Pereira, Heloise Anne, Edmond, OK, United States  
PA The Board of Regents of the University of Oklahoma, United States (U.S.  
corporation)  
PI US 6071879 20000606  
AI US 1999-260373 19990301 (9)  
RLI Continuation of Ser. No. US 1997-840519, filed on 21 Apr 1997, now  
patented, Pat. No. US 5877151 which is a continuation of Ser. No. US  
1995-482328, filed on 7 Jun 1995, now patented, Pat. No. US 5627262,  
issued on 6 May 1997 which is a continuation-in-part of Ser. No. US  
1994-235399, filed on 29 Apr 1994, now patented, Pat. No. US 5607916  
which is a continuation-in-part of Ser. No. US 1992-969931, filed on 30  
Oct 1992, now patented, Pat. No. US 5458874 which is a continuation of  
Ser. No. US 1992-855417, filed on 19 Mar 1992, now patented, Pat. No.  
US  
5484885 which is a continuation-in-part of Ser. No. US 1990-543151,  
filed on 25 Jun 1990, now abandoned which is a continuation-in-part of  
Ser. No. US 1989-375739, filed on 5 Jul 1989, now abandoned  
DT Utility  
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Moore,  
William W.  
LREP Dunlap, Coddling & Rogers, P.C.  
CLMN Number of Claims: 3  
ECL Exemplary Claim: 1  
DRWN 19 Drawing Figure(s); 19 Drawing Page(s)  
LN.CNT 806  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 6 OF 48 USPATFULL  
AN 2000:54074 USPATFULL

TI Antimicrobial cationic peptides  
IN Hancock, Robert E. W., Vancouver, Canada  
Karunaratne, Nedra, Kandy, Sri Lanka  
PA University of British Columbia, Vancouver, Canada (non-U.S.  
corporation)  
PI US 6057291 20000502  
AI US 1996-763226 19961210 (8)  
RLI Continuation-in-part of Ser. No. US 1996-658857, filed on 31 May 1996  
which is a continuation-in-part of Ser. No. US 1995-460464, filed on 2  
Jun 1995, now patented, Pat. No. US 5877274  
DT Utility  
EXNAM Primary Examiner: Prouty, Rebecca E.; Assistant Examiner: Longton,  
Enrique D.  
LREP Fish & Richardson P. C.  
CLMN Number of Claims: 10  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)  
LN.CNT 2740  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 7 OF 48 USPATFULL  
AN 2000:50681 USPATFULL  
TI Anti-gram-positive bacterial methods and materials  
IN Horwitz, Arnold, Los Angeles, CA, United States  
Lambert, Jr., Lewis H., Fremont, CA, United States  
Little, II, Roger G., Benicia, CA, United States  
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)  
PI US 6054431 20000425  
AI US 1998-119263 19980720 (9)  
RLI Continuation of Ser. No. US 1996-758116, filed on 25 Nov 1996, now  
patented, Pat. No. US 5783561 which is a continuation of Ser. No. US  
1995-372783, filed on 13 Jan 1995, now patented, Pat. No. US 5578572  
which is a continuation-in-part of Ser. No. US 1994-274299, filed on 11  
Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US  
1994-209762, filed on 11 Mar 1994, now patented, Pat. No. US 5733872  
which is a continuation-in-part of Ser. No. US 1994-183222, filed on 14  
Jan 1994, now abandoned  
DT Utility  
EXNAM Primary Examiner: MacMillan, Keith D.; Assistant Examiner: Ponnalun, P.  
LREP Marshall, O'Toole, Gerstein, Murray & Borun  
CLMN Number of Claims: 14  
ECL Exemplary Claim: 1  
DRWN 32 Drawing Figure(s); 32 Drawing Page(s)  
LN.CNT 6671  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 8 OF 48 USPATFULL  
AN 2000:40880 USPATFULL  
TI Polynucleotides encoding a cardiotrophin-like cytokine  
IN Shi, Yanggu, Gaithersburg, MD, United States  
Ruben, Steven M., Olney, MD, United States  
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.  
corporation)  
PI US 6046035 20000404  
AI US 1998-106182 19980629 (9)  
PRAI US 1997-51311 19970630 (60)  
DT Utility  
EXNAM Primary Examiner: Ulm, John; Assistant Examiner: Saoud, Christine  
LREP Human Genome Sciences Inc.  
CLMN Number of Claims: 5  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 3830  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 9 OF 48 USPATFULL  
AN 2000:34679 USPATFULL  
TI Antimicrobial cationic peptides  
IN Hancock, Robert E. W., Vancouver, Canada  
Karunaratne, Nedra, Vancouver, Canada  
PA University of British Columbia, Vancouver, Canada (non-U.S. corporation)  
PI US 6040435 20000321  
AI US 1996-658857 19960531 (8)  
RLI Continuation-in-part of Ser. No. US 1995-460464, filed on 2 Jun 1995,  
now patented, Pat. No. US 5877274  
DT Utility  
EXNAM Primary Examiner: Sisson, Bradley; Assistant Examiner: Longton, Enrique  
D.  
LREP Gary Cary Ware & Freidenrich LLP; Haile, Lisa A.  
CLMN Number of Claims: 2  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Figure(s); 9 Drawing Page(s)  
LN.CNT 2069  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 10 OF 48 USPATFULL  
AN 2000:34395 USPATFULL  
TI Assay for identifying agents which act on the ceramide-activated  
protein  
kinase, kinase suppressor of ras, and methods of using said agents  
IN Kolesnick, Richard N., New York, NY, United States  
Liu, Jun, Boston, MA, United States  
Zhang, Yuhua, New York, NY, United States  
PA Sloan-Kettering Institute for Cancer Research, New York, NY, United  
States (U.S. corporation)  
PI US 6040149 20000321  
AI US 1997-785247 19970110 (8)  
PRAI US 1996-9900 19960111 (60)  
DT Utility  
EXNAM Primary Examiner: Hobbs, Lisa J.  
LREP White, John P. Cooper & Dunham LLP  
CLMN Number of Claims: 3  
ECL Exemplary Claim: 1  
DRWN 57 Drawing Figure(s); 41 Drawing Page(s)  
LN.CNT 4300  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 11 OF 48 USPATFULL  
AN 2000:12617 USPATFULL  
TI H. influenzae HxuB and HxuC genes, proteins and methods of use  
IN Hansen, Eric J., Plano, TX, United States  
Cope, Leslie D., Mesquite, TX, United States  
Jarosik, Gregory P., Arlington, TX, United States  
Hanson, Mark S., Columbia, MD, United States  
PA Board of Regents, The University of Texas System, Austin, TX, United  
States (U.S. corporation)  
PI US 6020154 20000201  
AI US 1995-425843 19950420 (8)  
DT Utility  
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Srivastava,  
Devesh  
LREP Arnold, White & Durkee  
CLMN Number of Claims: 77  
ECL Exemplary Claim: 20  
DRWN 7 Drawing Figure(s); 6 Drawing Page(s)  
LN.CNT 4068  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 12 OF 48 USPATFULL  
AN 1999:170587 USPATFULL

TI Antimicrobial peptides and methods of use  
IN Selsted, Michael E., Irvine, CA, United States  
PA The Regents of University of California, Oakland, CA, United States  
(U.S. corporation)  
PI US 6008195 19991228  
AI US 1997-799149 19970214 (8)  
PRAI US 1996-11834 19960216 (60)  
DT Utility  
EXNAM Primary Examiner: Prouty, Rebecca E.  
LREP Gray Cary Ware & Freidenrich LLP; Haile, Lisa A.  
CLMN Number of Claims: 28  
ECL Exemplary Claim: 1  
DRWN 9 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 1671  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 13 OF 48 USPATFULL  
AN 1999:163462 USPATFULL  
TI Polynucleotides encoding myeloid progenitor inhibitory factor-1  
(MPIF-1)  
and polypeptides encoded thereby  
IN Ruben, Steven M., Olney, MD, United States  
Li, Haodong, Gaithersburg, MD, United States  
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.  
corporation)  
PI US 6001606 19991214  
AI US 1996-722719 19960930 (8)  
RLI Continuation-in-part of Ser. No. US 1995-446881, filed on 5 May 1995,  
now abandoned which is a continuation-in-part of Ser. No. US  
1995-465682, filed on 6 Jun 1995, now abandoned which is a  
continuation-in-part of Ser. No. US 1994-208339, filed on 8 Mar 1994,  
now patented, Pat. No. US 5504003 Ser. No. Ser. No. US 1995-468775,  
filed on 6 Jun 1995, now abandoned And Ser. No. WO 1996-US15592, filed  
on 27 Sep 1996 , said Ser. No. US 465682 which is a  
continuation-in-part  
of Ser. No. US 446881 , said Ser. No. US 468775 which is a  
continuation-in-part of Ser. No. US 446881  
PRAI US 1995-4517 19950929 (60)  
DT Utility  
EXNAM Primary Examiner: Mertz, Prema  
LREP Sterne, Kessler, Goldstein & Fox, P.L.L.C.  
CLMN Number of Claims: 74  
ECL Exemplary Claim: 1  
DRWN 53 Drawing Figure(s); 49 Drawing Page(s)  
LN.CNT 6406  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 14 OF 48 USPATFULL  
AN 1999:155689 USPATFULL  
TI Fine-tuned protegrins  
IN Chang, Conway C., San Francisco, CA, United States  
Gu, Chee Liang, Saratoga, CA, United States  
Chen, Jie, Belmont, CA, United States  
Steinberg, Deborah A., Saratoga, CA, United States  
Lehrer, Robert I., Santa Monica, CA, United States  
Harwig, deceased, Sylvia S.L., late of Woodland Hills, CA, United  
States  
by John Harwig, executor  
PA IntraBiotics Pharmaceuticals, Inc., Mountain View, CA, United States  
(U.S. corporation)  
PI US 5994306 19991130  
AI US 1996-752852 19961121 (8)  
RLI Continuation-in-part of Ser. No. US 1996-690921, filed on 1 Aug 1996,  
now abandoned which is a continuation-in-part of Ser. No. US  
1996-649811, filed on 17 May 1996, now abandoned which is a

continuation-in-part of Ser. No. US 1995-562346, filed on 22 Nov 1995, now abandoned which is a continuation-in-part of Ser. No. US 1995-499523, filed on 7 Jul 1995, now patented, Pat. No. US 5804558 which is a continuation-in-part of Ser. No. US 1995-451832, filed on 26 May 1995, now abandoned which is a continuation-in-part of Ser. No. WO 1994-US8305, filed on 20 Jul 1994 And Ser. No. US 1994-243879, filed on 17 May 1994, now patented, Pat. No. US 5708145 which is a continuation-in-part of Ser. No. US 1994-182483, filed on 13 Jan 1994, now patented, Pat. No. US 5693486 which is a continuation-in-part of Ser. No. US 1993-95769, filed on 26 Jul 1993, now patented, Pat. No. US 5464823 which is a continuation-in-part of Ser. No. US 1993-93926,

filed

on 20 Jul 1993, now abandoned

DT Utility

EXNAM Primary Examiner: Achutamurthy, Ponnathapura; Assistant Examiner: Moore,

William W.

LREP Pennie & Edmonds LLP

CLMN Number of Claims: 42

ECL Exemplary Claim: 1

DRWN 6 Drawing Figure(s); 9 Drawing Page(s)

LN.CNT 5488

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 15 OF 48 USPATFULL

AN 1999:145984 USPATFULL

TI Oral or intranasal vaccines using hydrophobic complexes having proteosomes and lipopolysaccharides

IN Lowell, George H., 6303 Western Run Dr., Baltimore, MD, United States 21215

PI US 5985284 19991116

AI US 1996-677302 19960709 (8)

RLI Continuation of Ser. No. US 1996-673756, filed on 29 Apr 1996 which is a

continuation of Ser. No. WO 1993-US10402, filed on 29 Oct 1993

DT Utility

EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Graser, Jennifer

LREP Morrison & Foerster LLP

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN 9 Drawing Figure(s); 9 Drawing Page(s)

LN.CNT 1535

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 16 OF 48 USPATFULL

AN 1999:27732 USPATFULL

TI Antimicrobial cationic peptides

IN Hancock, Robert E. W., Vancouver, Canada

Karunaratne, Nedra, Vancouver, Canada

PA University of British Columbia, Vancouver, Canada (non-U.S. corporation)

PI US 5877274 19990302

AI US 1995-460464 19950602 (8)

DT Utility

EXNAM Primary Examiner: Carlson, Karen Cochrane; Assistant Examiner: Longton, Enrique D.

LREP Fish & Richardson P.C.

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN 10 Drawing Figure(s); 10 Drawing Page(s)

LN.CNT 1008

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 17 OF 48 USPATFULL

AN 1999:27610 USPATFULL  
TI Method for inhibiting production of tumor necrosis factor  
IN Pereira, Heloise Anne, Edmond, OK, United States  
PA The Board of Regents of the University of Oklahoma, United States (U.S. corporation)  
PI US 5877151 19990302  
AI US 1997-840519 19970421 (8)  
RLI Continuation of Ser. No. US 1995-482328, filed on 7 Jun 1995, now patented, Pat. No. US 5627262, issued on 6 May 1997 which is a continuation-in-part of Ser. No. US 1994-235399, filed on 29 Apr 1994, now patented, Pat. No. US 5607916, issued on 4 Mar 1997 which is a continuation-in-part of Ser. No. US 1992-939931, filed on 30 Oct 1992, now patented, Pat. No. US 5458874, issued on 17 Oct 1995 which is a continuation of Ser. No. US 1992-855417, filed on 19 Mar 1992, now patented, Pat. No. US 5484885, issued on 16 Jan 1996 which is a continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-375739, filed on 5 Jul 1989, now abandoned  
DT Utility  
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Moore, William W.  
LREP Dunlap & Coddington, P.C.  
CLMN Number of Claims: 2  
ECL Exemplary Claim: 1  
DRWN 19 Drawing Figure(s); 19 Drawing Page(s)  
LN.CNT 804  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 18 OF 48 USPATFULL

AN 1999:1767 USPATFULL  
TI Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof  
IN Little, II, Roger G., Benicia, CA, United States  
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)  
PI US 5856438 19990105  
AI US 1995-485445 19950607 (8)  
RLI Continuation of Ser. No. US 1994-306473, filed on 15 Sep 1994, now patented, Pat. No. US 5652332 And a continuation-in-part of Ser. No. US 1994-273540, filed on 11 Jul 1994, now abandoned And Ser. No. US 1994-274299, filed on 11 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-209762, filed on 11 Mar 1994, now patented, Pat. No. US 5696085 which is a continuation-in-part of Ser. No. US 1994-183222, filed on 14 Jan 1994, now abandoned, said

Ser.

No. US 306473 which is a continuation-in-part of Ser. No. US 209762, said Ser. No. US 183222 which is a continuation-in-part of Ser. No. US 1993-93202, filed on 15 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-30644, filed on 12 Mar 1993, now patented, Pat. No. US 5348942

DT Utility  
EXNAM Primary Examiner: Davenport, Avis M.  
LREP McAndrews, Held & Malloy, Ltd.  
CLMN Number of Claims: 11  
ECL Exemplary Claim: 1  
DRWN 94 Drawing Figure(s); 78 Drawing Page(s)  
LN.CNT 5756  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 19 OF 48 USPATFULL

AN 1998:162479 USPATFULL  
TI Therapeutic uses of bactericidal/permeability increasing protein products  
IN Little, II, Roger G., Benicia, CA, United States  
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)  
PI US 5854214 19981229  
AI US 1995-466826 19950606 (8)

RLI Continuation of Ser. No. US 1995-415158, filed on 31 Mar 1995, now patented, Pat. No. US 5639727 which is a continuation-in-part of Ser. No. US 1993-30644, filed on 12 Mar 1993, now patented, Pat. No. US 5348942  
DT Utility  
EXNAM Primary Examiner: Kemmerer, Elizabeth C.; Assistant Examiner: Romeo, David S.  
LREP McAndrews, Held & Malloy, Ltd.  
CLMN Number of Claims: 2  
ECL Exemplary Claim: 1  
DRWN 31 Drawing Figure(s); 31 Drawing Page(s)  
LN.CNT 1552  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 20 OF 48 USPATFULL  
AN 1998:159736 USPATFULL  
TI Methods for recombinant microbial production of fusion proteins and BPI-derived peptides  
IN Better, Marc D., Los Angeles, CA, United States  
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)  
PI US 5851802 19981222  
AI US 1996-621803 19960322 (8)  
DT Utility  
EXNAM Primary Examiner: Spector, Lorraine  
LREP McAndrews, Held & Malloy, Ltd.  
CLMN Number of Claims: 15  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 4280  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 21 OF 48 USPATFULL  
AN 1998:154080 USPATFULL  
TI DNA encoding tumor necrosis factor stimulated gene 6 (TSG-6)  
IN Lee, Tae Ho, Daejeon, Korea, Republic of  
Wisniewski, Hans-Georg, New York, NY, United States  
Vilcek, Jan, New York, NY, United States  
PA New York University, New York, NY, United States (U.S. corporation)  
PI US 5846763 19981208  
AI US 1994-242097 19940513 (8)  
RLI Continuation-in-part of Ser. No. US 1993-24868, filed on 1 Mar 1993, now  
patented, Pat. No. US 5386013 which is a continuation of Ser. No. US 1991-642312, filed on 14 Jan 1991, now abandoned  
DT Utility  
EXNAM Primary Examiner: Draper, Garnette D.; Assistant Examiner: Kemmerer, Elizabeth C.  
LREP Browdy and Neimark  
CLMN Number of Claims: 14  
ECL Exemplary Claim: 2  
DRWN 48 Drawing Figure(s); 28 Drawing Page(s)  
LN.CNT 3807  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 22 OF 48 USPATFULL  
AN 1998:144206 USPATFULL  
TI Polypeptides of lipopolysaccharide binding protein  
IN Han, Jiahuai, La Jolla, CA, United States  
Ulevitch, Richard J., Del Mar, CA, United States  
Tobias, Peter S., San Diego, CA, United States  
PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)  
PI US 5837810 19981117  
AI US 1994-215089 19940315 (8)  
DT Utility



EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Johnson, Nancy A.  
LREP Fish & Richardson, P.C.  
CLMN Number of Claims: 1  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Figure(s); 10 Drawing Page(s)  
LN.CNT 1162  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 23 OF 48 USPATFULL  
AN 1998:144078 USPATFULL  
TI Therapeutic uses of bactericidal/permeability increasing protein products  
IN Little, II, Roger G., Benicia, CA, United States  
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)  
PI US 5837678 19981117  
AI US 1995-466624 19950606 (8)  
RLI Continuation of Ser. No. US 1995-415158, filed on 31 Mar 1995 which is a  
continuation-in-part of Ser. No. US 1993-30644, filed on 12 Mar 1993, now patented, Pat. No. US 5348942  
DT Utility  
EXNAM Primary Examiner: Jagannathan, Vasu S.; Assistant Examiner: Kim, Hyosuk  
LREP Marshall, O'Toole, Gerstein, Murray & Borun  
CLMN Number of Claims: 7  
ECL Exemplary Claim: 1  
DRWN 31 Drawing Figure(s); 31 Drawing Page(s)  
LN.CNT 1558  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 24 OF 48 USPATFULL  
AN 1998:111899 USPATFULL  
TI Therapeutic uses of bactericidal/permeability increasing protein (BPI) protein products  
IN Little, II, Roger G., Benicia, CA, United States  
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)  
PI US 5807818 19980915  
AI US 1995-435855 19950505 (8)  
RLI Division of Ser. No. US 1995-415158, filed on 31 Mar 1995, now patented,  
Pat. No. US 5639727 which is a continuation of Ser. No. US 1993-93202, filed on 15 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-30644, filed on 12 Mar 1993, now patented, Pat. No. US 5348942  
DT Utility  
EXNAM Primary Examiner: Kemmerer, Elizabeth C.; Assistant Examiner: Lathrop, Brian  
LREP McAndrews, Held & Malloy, Ltd.  
CLMN Number of Claims: 2  
ECL Exemplary Claim: 1  
DRWN 31 Drawing Figure(s); 31 Drawing Page(s)  
LN.CNT 1542  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 25 OF 48 USPATFULL  
AN 1998:92001 USPATFULL  
TI Treatment of endotoxin-associated disorders with cationic peptides  
IN Hancock, Robert E. W., Vancouver, Canada  
Piers, Kevin L., Richmond, Canada  
Brown, Melissa H., Vancouver, Canada  
Kelly, Niamh, Vancouver, Canada  
PA University of British Columbia, Vancouver, Canada (non-U.S. corporation)  
PI US 5789377 19980804

AI US 1995-405234 19950313 (8)  
RLI Continuation-in-part of Ser. No. US 1993-110502, filed on 20 Aug 1993,  
now abandoned which is a continuation-in-part of Ser. No. US  
1992-933492, filed on 21 Aug 1992, now abandoned  
DT Utility  
EXNAM Primary Examiner: Patterson, Jr., Charles L.  
LREP Fish & Richardson, P.C.  
CLMN Number of Claims: 2  
ECL Exemplary Claim: 1  
DRWN 24 Drawing Figure(s); 17 Drawing Page(s)  
LN.CNT 1454  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 26 OF 48 USPATFULL  
AN 1998:85936 USPATFULL  
TI Anti-gram-positive bacterial methods and materials  
IN Horwitz, Arnold, Los Angeles, CA, United States  
Lambert, Jr., Lewis H., Fremont, CA, United States  
Little, II, Roger G., Benicia, CA, United States  
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)  
PI US 5783561 19980721  
AI US 1996-758116 19961125 (8)  
RLI Continuation of Ser. No. US 1995-372783, filed on 13 Jan 1995, now  
patented, Pat. No. US 5578572 which is a continuation-in-part of Ser.  
No. US 1994-274299, filed on 11 Jul 1994, now abandoned which is a  
continuation-in-part of Ser. No. US 1994-209762, filed on 11 Mar 1994,  
now patented, Pat. No. US 5733872 which is a continuation-in-part of  
Ser. No. US 1994-183222, filed on 14 Jan 1994, now abandoned  
DT Utility  
EXNAM Primary Examiner: Achutamurthy, Ponnathapura  
LREP Marshall, O'Toole, Gerstein, Murray & Borun  
CLMN Number of Claims: 24  
ECL Exemplary Claim: 1  
DRWN 32 Drawing Figure(s); 32 Drawing Page(s)  
LN.CNT 6127  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 27 OF 48 USPATFULL  
AN 1998:82718 USPATFULL  
TI Anti-LPS factor from horseshoe crabs and methods of use  
IN Wainwright, Norman R., Falmouth, MA, United States  
PA Marine Biological Laboratory, Woods Hole, MA, United States (U.S.  
corporation)  
PI US 5780429 19980714  
AI US 1995-577464 19951222 (8)  
DT Utility  
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner:  
Delacroix-Muirheid, C.  
LREP Hale and Dorr LLP  
CLMN Number of Claims: 6  
ECL Exemplary Claim: 4  
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 843  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 28 OF 48 USPATFULL  
AN 1998:72434 USPATFULL  
TI DNA encoding macrophage inflammatory protein-1.gamma.  
IN Beutler, Bruce A., Dallas, TX, United States  
Poltorak, Alexander N., Dallas, TX, United States  
PA Board of Regents, The University of Texas System, Austin, TX, United  
States (U.S. corporation)  
PI US 5770402 19980623  
AI US 1995-418032 19950405 (8)  
DT Utility

EXNAM Primary Examiner: Ulm, John; Assistant Examiner: Mertz, Prema  
LREP Arnold, White & Durkee  
CLMN Number of Claims: 30  
ECL Exemplary Claim: 1  
DRWN 15 Drawing Figure(s); 13 Drawing Page(s)  
LN.CNT 2834  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 29 OF 48 USPATFULL  
AN 1998:65346 USPATFULL  
TI Biologically active peptides from functional domains of  
bactericidal/permeability-increasing protein and uses thereof  
IN Little, Roger G., Benicia, CA, United States  
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)  
PI US 5763567 19980609  
AI US 1995-473344 19950607 (8)  
RLI Continuation of Ser. No. US 1994-209762, filed on 11 Mar 1994 which is  
a  
continuation-in-part of Ser. No. US 1994-183222, filed on 14 Jan 1994,  
now abandoned which is a continuation-in-part of Ser. No. US  
1993-93202,  
filed on 15 Jul 1993, now abandoned which is a continuation-in-part of  
Ser. No. US 1993-30644, filed on 12 Mar 1993, now patented, Pat. No. US  
5348942  
DT Utility  
EXNAM Primary Examiner: Carlson, Karen C.  
LREP McAndrews, Held & Malloy, Ltd.  
CLMN Number of Claims: 7  
ECL Exemplary Claim: 1  
DRWN 86 Drawing Figure(s); 70 Drawing Page(s)  
LN.CNT 3868  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 30 OF 48 USPATFULL  
AN 1998:48450 USPATFULL  
TI Combinational therapeutic methods employing nitric oxide scavengers and  
compositions useful therefor  
IN Lai, Ching-San, Encinitas, CA, United States  
PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)  
PI US 5747532 19980505  
AI US 1995-561594 19951121 (8)  
DT Utility  
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Smith, Lyman H.  
LREP Gray Cary Ware & Freidenrich; Reiter, Stephen E.  
CLMN Number of Claims: 33  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)  
LN.CNT 1112  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 31 OF 48 USPATFULL  
AN 1998:33895 USPATFULL  
TI Biologically active peptides from functional domains of  
bactericidal/permeability-increasing protein and uses thereof  
IN Little, Roger G., Benicia, CA, United States  
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)  
PI US 5733872 19980331  
AI US 1994-209762 19940311 (8)  
RLI Continuation-in-part of Ser. No. US 1994-183222, filed on 14 Jan 1994,  
now abandoned which is a continuation-in-part of Ser. No. US  
1993-93202,  
filed on 15 Jul 1993, now abandoned which is a continuation-in-part of  
Ser. No. US 1993-30644, filed on 12 Mar 1993, now patented, Pat. No. US  
5348942  
DT Utility

EXNAM Primary Examiner: Carlson, Karen C.  
LREP McAndrews, Held & Malloy, Ltd.  
CLMN Number of Claims: 45  
ECL Exemplary Claim: 1  
DRWN 86 Drawing Figure(s); 70 Drawing Page(s)  
LN.CNT 3967  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 32 OF 48 USPATFULL  
AN 1998:31119 USPATFULL  
TI Lipopolysaccharide binding protein derivatives  
IN Gazzano-Santoro, Helene, San Bruno, CA, United States  
Theofan, Georgia, Torrance, CA, United States  
Trown, Patrick W., Danville, CA, United States  
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)  
PI US 5731415 19980324  
AI US 1994-261660 19940617 (8)  
RLI Continuation-in-part of Ser. No. US 1993-79510, filed on 17 Jun 1993,  
now abandoned  
DT Utility  
EXNAM Primary Examiner: Jagannathan, Vasu S.; Assistant Examiner: Romeo,  
David  
S.  
LREP Marshall, O'Toole, Gerstein, Murray & Borun  
CLMN Number of Claims: 10  
ECL Exemplary Claim: 1  
DRWN 26 Drawing Figure(s); 25 Drawing Page(s)  
LN.CNT 2186  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 33 OF 48 USPATFULL  
AN 97:107054 USPATFULL  
TI Treatment of **endotoxin**-associated disorders with cationic  
peptides  
IN Hancock, Robert E. W., Vancouver, Canada  
Piers, Kevin L., Red Deer, Canada  
Brown, Melissa H., Canterbury, Australia  
Kelly, Niamh, Vancouver, Canada  
PA University of British Columbia, Vancouver, Canada (non-U.S.  
corporation)  
PI US 5688767 19971118  
AI US 1996-614516 19960313 (8)  
RLI Division of Ser. No. US 1995-405234, filed on 13 Mar 1995 which is a  
continuation-in-part of Ser. No. US 1993-110502, filed on 20 Aug 1993,  
now abandoned which is a continuation-in-part of Ser. No. US  
1992-933492, filed on 21 Aug 1992, now abandoned  
DT Utility  
EXNAM Primary Examiner: Patterson, Jr, Charles L.  
LREP Fish & Richardson, P.C.  
CLMN Number of Claims: 6  
ECL Exemplary Claim: 1  
DRWN 26 Drawing Figure(s); 19 Drawing Page(s)  
LN.CNT 1709  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 34 OF 48 USPATFULL  
AN 97:51974 USPATFULL  
TI Therapeutic uses of bactericidal/permeability increasing protein  
products  
IN Little, II, Roger G., Benicia, CA, United States  
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)  
PI US 5639727 19970617  
AI US 1995-415158 19950331 (8)  
RLI Continuation of Ser. No. US 1993-93202, filed on 15 Jul 1993, now  
abandoned which is a continuation-in-part of Ser. No. US 1993-30644,

filed on 12 Mar 1993, now patented, Pat. No. US 5348942  
DT Utility  
EXNAM Primary Examiner: Patterson, Jr., Charles L.; Assistant Examiner: Kim, Hydsuk  
LREP Marshall, O'Toole, Gerstein, Murray & Borun  
CLMN Number of Claims: 5  
ECL Exemplary Claim: 1  
DRWN 31 Drawing Figure(s); 31 Drawing Page(s)  
LN.CNT 1570  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 35 OF 48 USPATFULL  
AN 97:38605 USPATFULL  
TI Method and composition for the treatment of septic shock  
IN Pereira, Heloise A., Edmond, OK, United States  
PA The Board of Regents of the University of Oklahoma, Norman, OK, United States (U.S. corporation)  
PI US 5627262 19970506  
AI US 1995-482328 19950607 (8)  
RLI Continuation-in-part of Ser. No. US 1994-235399, filed on 29 Apr 1994, now patented, Pat. No. US 5607916, issued on 4 Mar 1997 which is a continuation-in-part of Ser. No. US 1992-969931, filed on 30 Oct 1992, now patented, Pat. No. US 5458874, issued on 17 Oct 1995 which is a continuation of Ser. No. US 1992-855417, filed on 19 Mar 1992, now patented, Pat. No. US 5484885, issued on 16 Jan 1996 which is a continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-375739, filed on 5 Jul 1989, now abandoned  
DT Utility  
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Moore, William W.  
LREP Dunlap & Coddington, P.C.  
CLMN Number of Claims: 11  
ECL Exemplary Claim: 1  
DRWN 19 Drawing Figure(s); 19 Drawing Page(s)  
LN.CNT 839  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 36 OF 48 USPATFULL  
AN 97:29335 USPATFULL  
TI Methods and compositions for detecting lipopolysaccharides using CAP18 fragments  
IN Larrick, James W., Woodside, CA, United States  
Wright, Susan C., Saratoga, CA, United States  
PA Panorama Research, Inc., Mountain View, CA, United States (U.S. corporation)  
PI US 5618675 19970408  
AI US 1994-313681 19940927 (8)  
RLI Continuation-in-part of Ser. No. US 1992-916961, filed on 16 Jul 1992, now patented, Pat. No. US 5277707 And Ser. No. US 1992-916765, filed on 17 Jul 1992, now abandoned  
DT Utility  
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Portner, Ginny Allen  
LREP Townsend & Townsend & Crew LLP  
CLMN Number of Claims: 5  
ECL Exemplary Claim: 1  
DRWN 35 Drawing Figure(s); 23 Drawing Page(s)  
LN.CNT 1963  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 37 OF 48 USPATFULL  
AN 97:25018 USPATFULL  
TI Method of making inosine monophosphate derivatives and immunopotentiating uses thereof  
IN Hadden, John W., Tampa, FL, United States

PA Giner-Sorolla, Alfredo, Tampa, FL, United States  
The University of South Florida, Tampa, FL, United States (U.S. corporation)  
PI US 5614504 19970325  
AI US 1995-426682 19950421 (8)  
RLI Continuation-in-part of Ser. No. US 1992-995550, filed on 22 Dec 1992, now abandoned which is a continuation of Ser. No. US 1990-561979, filed on 1 Aug 1990, now abandoned  
DT Utility  
EXNAM Primary Examiner: Kight, John; Assistant Examiner: Crane, L. Eric  
LREP Kohn & Associates  
CLMN Number of Claims: 27  
ECL Exemplary Claim: 1  
DRWN 19 Drawing Figure(s); 9 Drawing Page(s)  
LN.CNT 2194  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 38 OF 48 USPATFULL

AN 97:7685 USPATFULL  
TI Lipid-A analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities  
IN Kamireddy, Balreddy, Hockessin, DE, United States  
Darsley, Michael J., Rockville, MD, United States  
Simpson, David M., Adelphi, MD, United States  
Massey, Richard J., Rockville, MD, United States  
PA Igen, Inc., Gaithersburg, MD, United States (U.S. corporation)  
PI US 5597573 19970128  
AI US 1995-405438 19950314 (8)  
RLI Continuation-in-part of Ser. No. US 1991-761868, filed on 3 Sep 1991  
And

a continuation-in-part of Ser. No. US 1993-37261, filed on 26 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-871229, filed on 17 Apr 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-861362, filed on 27 Mar 1992, now abandoned

DT Utility  
EXNAM Primary Examiner: Kim, Kay K. A.  
LREP Curtis, Morris & Safford; Evans, Barry; Salkeld, Pamela G.  
CLMN Number of Claims: 6  
ECL Exemplary Claim: 1  
DRWN 53 Drawing Figure(s); 53 Drawing Page(s)  
LN.CNT 4095  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 39 OF 48 USPATFULL

AN 97:3817 USPATFULL  
TI Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors  
IN Kamireddy, Balreddy, Rockville, MD, United States  
Darsley, Michael J., Rockville, MD, United States  
Simpson, David M., Adelphi, MD, United States  
Massey, Richard J., Rockville, MD, United States  
PA IGEN Incorporated, Gaithersburg, MD, United States (U.S. corporation)  
PI US 5593969 19970114  
AI US 1993-123590 19930917 (8)  
RLI Continuation of Ser. No. US 1992-871229, filed on 17 Apr 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-861362, filed on 27 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-761868, filed on 3 Sep 1991  
DT Utility  
EXNAM Primary Examiner: Kunz, Gary L.; Assistant Examiner: Fonda, Kathleen Kahler  
LREP Curtis, Morris & Safford; Evans, Barry; Salkeld, Pamela G.  
CLMN Number of Claims: 4

ECL Exemplary Claim: 1  
DRWN 47 Drawing Figure(s); 47 Drawing Page(s)  
LN.CNT 4116  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 40 OF 48 USPATFULL  
AN 96:108941 USPATFULL  
TI Anti-gram-positive bacterial methods and materials  
IN Horwitz, Arnold, Los Angeles, CA, United States  
Lambert, Jr., Lewis H., Fremont, CA, United States  
Little, II, Roger G., Benicia, CA, United States  
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)  
PI US 5578572 19961126  
AI US 1995-372783 19950113 (8)  
RLI Continuation-in-part of Ser. No. US 1994-274299, filed on 11 Jul 1994  
which is a continuation-in-part of Ser. No. US 1994-209762, filed on 11  
Mar 1994 which is a continuation-in-part of Ser. No. US 1994-183222,  
filed on 14 Jan 1994, now abandoned  
DT Utility  
EXNAM Primary Examiner: Achutamurthy, Ponnathapura  
LREP Marshall, O'Toole, Gerstein, Murray & Borun  
CLMN Number of Claims: 13  
ECL Exemplary Claim: 1  
DRWN 32 Drawing Figure(s); 32 Drawing Page(s)  
LN.CNT 4639  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 41 OF 48 USPATFULL  
AN 95:69093 USPATFULL  
TI Method of inhibiting blood coagulation in extracorporeal circulation by  
inhibiting human tissue factor  
IN Edgington, Thomas S., La Jolla, CA, United States  
Colman, Robert W., Moylan, PA, United States  
Kappelmayer, Janos, Debrecen, Hungary  
Edmunds, Jr., L. Henry, Bryn Mawr, PA, United States  
Bernabei, Alvise, Philadelphia, PA, United States  
PA The Scripps Research Institute, La Jolla, CA, United States (U.S.  
corporation)  
Trustees of the University of Pennsylvania, Philadelphia, PA, United  
States (U.S. corporation)  
Temple University - Of the Commonwealth Systems of Higher Education,  
Philadelphia, PA, United States (U.S. corporation)  
PI US 5437864 19950801  
AI US 1992-977281 19921116 (7)  
RLI Continuation-in-part of Ser. No. US 1988-165939, filed on 9 Mar 1988,  
now patented, Pat. No. US 5223427 which is a continuation-in-part of  
Ser. No. US 1987-67103, filed on 25 Jun 1987, now patented, Pat. No. US  
5110730 which is a continuation-in-part of Ser. No. US 1987-33047,  
filed  
on 31 Mar 1987, now abandoned  
DT Utility  
EXNAM Primary Examiner: Nucker, Christine M.; Assistant Examiner: Cunningham,  
T.  
LREP Spensley Horn Jubas & Lubitz  
CLMN Number of Claims: 9  
ECL Exemplary Claim: 1  
DRWN 31 Drawing Figure(s); 23 Drawing Page(s)  
LN.CNT 3505  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 42 OF 48 USPATFULL  
AN 95:54452 USPATFULL  
TI DNA encoding cytokine-induced protein, TSG-14  
IN Lee, Tae H., Cambridge, MA, United States  
Lee, Gene W., New York, NY, United States

Vilcek, Jan, New York, NY, United States  
PA New York University, New York, NY, United States (U.S. corporation)  
PI US 5426181 19950620  
AI US 1992-929580 19920814 (7)  
RLI Continuation of Ser. No. US 1991-640492, filed on 14 Jan 1991, now abandoned  
DT Utility  
EXNAM Primary Examiner: Draper, Garnette D.; Assistant Examiner: Kemmerer, Elizabeth C.  
LREP Browdy and Neimark  
CLMN Number of Claims: 8  
ECL Exemplary Claim: 1  
DRWN 36 Drawing Figure(s); 19 Drawing Page(s)  
LN.CNT 3175  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 43 OF 48 USPATFULL  
AN 95:9803 USPATFULL  
TI Tumor necrosis factor-induced protein TSG-6  
IN Lee, Tae H., Piscataway, NJ, United States  
Wisniewski, Hans-Georg, Spring Valley, NY, United States  
Vilcek, Jan, New York, NY, United States  
PA New York University, New York, NY, United States (U.S. corporation)  
PI US 5386013 19950131  
AI US 1993-24868 19930301 (8)  
RLI Continuation of Ser. No. US 1991-642312, filed on 14 Jan 1991, now abandoned  
DT Utility  
EXNAM Primary Examiner: Draper, Garnette D.; Assistant Examiner: Kemmerer, Elizabeth C.  
LREP Browdy and Neimark  
CLMN Number of Claims: 2  
ECL Exemplary Claim: 1  
DRWN 50 Drawing Figure(s); 20 Drawing Page(s)  
LN.CNT 2952  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 44 OF 48 USPATFULL  
AN 94:82236 USPATFULL  
TI Therapeutic uses of bactericidal/permeability increasing protein products  
IN Little, II, Roger G., Benicia, CA, United States  
Gazzano-Santoro, Helene, San Bruno, CA, United States  
Parent, James B., Oakland, CA, United States  
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)  
PI US 5348942 19940920  
AI US 1993-30644 19930312 (8)  
DT Utility  
EXNAM Primary Examiner: Furman, Keith C.  
LREP Marshall, O'Toole, Gerstein, Murray & Borun  
CLMN Number of Claims: 2  
ECL Exemplary Claim: 1  
DRWN 13 Drawing Figure(s); 8 Drawing Page(s)  
LN.CNT 997  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 45 OF 48 USPATFULL  
AN 94:66475 USPATFULL  
TI Recombinant, non-glycosylated bpi protein and uses thereof  
IN Scott, Randal W., Cupertino, CA, United States  
Marra, Marian N., San Mateo, CA, United States  
PA INCYTE Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)  
PI US 5334584 19940802  
AI US 1992-990044 19921214 (7)



DCD 20090218  
RLI Continuation of Ser. No. US 1991-681551, filed on 5 Apr 1991, now patented, Pat. No. US 5171739 which is a continuation-in-part of Ser. No. US 1990-567016, filed on 13 Aug 1990 which is a continuation-in-part of Ser. No. US 1990-468696, filed on 19 Jan 1990, now patented, Pat. No. US 5089274 which is a continuation-in-part of Ser. No. US 1989-310842, filed on 14 Feb 1989, now abandoned  
DT Utility  
EXNAM Primary Examiner: Wityshyn, Michael G.; Assistant Examiner: Koh, Choon P.  
LREP White, John P.  
CLMN Number of Claims: 30  
ECL Exemplary Claim: 1  
DRWN 53 Drawing Figure(s); 53 Drawing Page(s)  
LN.CNT 2041  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 46 OF 48 USPATFULL  
AN 94:37931 USPATFULL  
TI Treatment of **endotoxin**-associated shock and prevention thereof using a BPI protein  
IN Scott, Randal W., Cupertino, CA, United States  
Marra, Marian N., San Mateo, CA, United States  
PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)  
PI US 5308834 19940503  
AI US 1992-990662 19921214 (7)  
DCD 20091215  
RLI Division of Ser. No. US 1991-681551, filed on 5 Apr 1991, now patented, Pat. No. US 5171739 which is a continuation-in-part of Ser. No. US 1990-567016, filed on 13 Aug 1990 which is a continuation-in-part of Ser. No. US 1990-468696, filed on 22 Jan 1990, now patented, Pat. No. US 5089274 which is a continuation-in-part of Ser. No. US 1989-310842, filed on 14 Feb 1989, now abandoned  
DT Utility  
EXNAM Primary Examiner: Wityshyn, Michael G.; Assistant Examiner: Koh, Choon  
LREP White, John P.  
CLMN Number of Claims: 3  
ECL Exemplary Claim: 1  
DRWN 45 Drawing Figure(s); 53 Drawing Page(s)  
LN.CNT 1924  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 47 OF 48 USPATFULL  
AN 93:22623 USPATFULL  
TI Recombinant vectors for Haemophilus influenzae peptides and proteins  
IN Anilionis, Algis, Pittsford, NY, United States  
Seid, Jr., Robert C., San Francisco, CA, United States  
Deich, Robert A., Rochester, NY, United States  
Zlotnick, Gary W., Penfield, NY, United States  
Green, Bruce A., Pittsford, NY, United States  
PA Praxis Biologics, Inc., Rochester, NY, United States (U.S. corporation)  
PI US 5196338 19930323  
AI US 1990-480396 19900215 (7)  
RLI Division of Ser. No. US 1989-396572, filed on 21 Aug 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-239572, filed on 1 Sep 1988, now patented, Pat. No. US 5098997 which is a continuation-in-part of Ser. No. US 1987-132073, filed on 11 Dec 1987, now abandoned which is a continuation-in-part of Ser. No. US 1987-20849, filed on 2 Mar 1987, now abandoned which is a continuation-in-part of

Ser. No. US 1986-948364, filed on 31 Dec 1986, now abandoned  
DT Utility  
EXNAM Primary Examiner: Lacey, David L.; Assistant Examiner: Ulm, John D.  
LREP Gordon, Alan M.; Baldwin, Geraldine F.  
CLMN Number of Claims: 19  
ECL Exemplary Claim: 1  
DRWN 38 Drawing Figure(s); 33 Drawing Page(s)  
LN.CNT 3534  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 48 OF 48 USPATFULL  
AN 92:103053 USPATFULL  
TI Treatment of **endotoxin**-associated shock and prevention  
thereof using a BPI protein  
IN Scott, Randal W., Cupertino, CA, United States  
Marra, Marian N., San Mateo, CA, United States  
PA Incyte Pharmaceuticals, Inc., Redwood City, CA, United States (U.S.  
corporation)  
PI US 5171739 19921215  
AI US 1991-681551 19910405 (7)  
DCD 20090218  
RLI Continuation-in-part of Ser. No. US 1990-567016, filed on 13 Aug 1990  
which is a continuation-in-part of Ser. No. US 1990-468696, filed on 22  
Jan 1990, now patented, Pat. No. US 5089274 which is a  
continuation-in-part of Ser. No. US 1989-310842, filed on 14 Feb 1989,  
now abandoned  
DT Utility  
EXNAM Primary Examiner: Cashion, Jr., Merrell C.; Assistant Examiner: Koh,  
Choon P.  
LREP White, John P.  
CLMN Number of Claims: 6  
ECL Exemplary Claim: 1  
DRWN 51 Drawing Figure(s); 51 Drawing Page(s)  
LN.CNT 1654  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.